IE922144A1 - Benzomorphanes and their use as pharmaceuticals - Google Patents
Benzomorphanes and their use as pharmaceuticalsInfo
- Publication number
- IE922144A1 IE922144A1 IE214492A IE922144A IE922144A1 IE 922144 A1 IE922144 A1 IE 922144A1 IE 214492 A IE214492 A IE 214492A IE 922144 A IE922144 A IE 922144A IE 922144 A1 IE922144 A1 IE 922144A1
- Authority
- IE
- Ireland
- Prior art keywords
- group
- benzomorphan
- methyl
- hydroxy
- alkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 26
- 125000003118 aryl group Chemical group 0.000 claims abstract description 17
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 10
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 5
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 5
- 150000002367 halogens Chemical class 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 207
- 239000000203 mixture Substances 0.000 claims description 118
- -1 hydroxy, methyl Chemical group 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 238000002360 preparation method Methods 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 4
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 156
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 135
- 238000002844 melting Methods 0.000 description 115
- 230000008018 melting Effects 0.000 description 115
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 84
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 79
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 239000000126 substance Substances 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 44
- 239000002585 base Substances 0.000 description 41
- 239000000243 solution Substances 0.000 description 31
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- 238000004440 column chromatography Methods 0.000 description 26
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 229960004132 diethyl ether Drugs 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- 239000007858 starting material Substances 0.000 description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 238000001704 evaporation Methods 0.000 description 21
- 230000008020 evaporation Effects 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000012452 mother liquor Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 229910021529 ammonia Inorganic materials 0.000 description 15
- 238000002425 crystallisation Methods 0.000 description 15
- NBEMORIANHKPTH-GSVOUGTGSA-N (2r)-2-methoxypropanoyl chloride Chemical compound CO[C@H](C)C(Cl)=O NBEMORIANHKPTH-GSVOUGTGSA-N 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 239000012280 lithium aluminium hydride Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- NBEMORIANHKPTH-VKHMYHEASA-N (2s)-2-methoxypropanoyl chloride Chemical compound CO[C@@H](C)C(Cl)=O NBEMORIANHKPTH-VKHMYHEASA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 239000013543 active substance Substances 0.000 description 11
- 230000010933 acylation Effects 0.000 description 11
- 238000005917 acylation reaction Methods 0.000 description 11
- 229940051805 benzomorphan derivative analgesics Drugs 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000002274 desiccant Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 238000006722 reduction reaction Methods 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 150000003840 hydrochlorides Chemical class 0.000 description 9
- 239000013067 intermediate product Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 230000020477 pH reduction Effects 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 239000000155 melt Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- IHRUWHJSVMOZTQ-JTQLQIEISA-N [(2s)-2-methoxypropyl] 4-methylbenzenesulfonate Chemical compound CO[C@@H](C)COS(=O)(=O)C1=CC=C(C)C=C1 IHRUWHJSVMOZTQ-JTQLQIEISA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 3
- RRWASFFSKLPJMJ-ACMTZBLWSA-N (1S,9R)-10-azatricyclo[7.3.1.02,7]trideca-2,4,6-triene hydrochloride Chemical compound Cl.C1C2=CC=CC=C2[C@H]2CCN[C@@H]1C2 RRWASFFSKLPJMJ-ACMTZBLWSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- IHRUWHJSVMOZTQ-SNVBAGLBSA-N [(2r)-2-methoxypropyl] 4-methylbenzenesulfonate Chemical compound CO[C@H](C)COS(=O)(=O)C1=CC=C(C)C=C1 IHRUWHJSVMOZTQ-SNVBAGLBSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 229940052303 ethers for general anesthesia Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- DRPAGHBRGYBOLS-SCSAIBSYSA-N (2r)-2-methoxybutanoyl chloride Chemical compound CC[C@@H](OC)C(Cl)=O DRPAGHBRGYBOLS-SCSAIBSYSA-N 0.000 description 2
- YTTFFPATQICAQN-SCSAIBSYSA-N (2r)-2-methoxypropan-1-ol Chemical compound CO[C@H](C)CO YTTFFPATQICAQN-SCSAIBSYSA-N 0.000 description 2
- XMTKNMQAPNHLJP-MRVPVSSYSA-N (2r)-2-phenylmethoxypropanoyl chloride Chemical compound ClC(=O)[C@@H](C)OCC1=CC=CC=C1 XMTKNMQAPNHLJP-MRVPVSSYSA-N 0.000 description 2
- DRPAGHBRGYBOLS-BYPYZUCNSA-N (2s)-2-methoxybutanoyl chloride Chemical compound CC[C@H](OC)C(Cl)=O DRPAGHBRGYBOLS-BYPYZUCNSA-N 0.000 description 2
- YTTFFPATQICAQN-BYPYZUCNSA-N (2s)-2-methoxypropan-1-ol Chemical compound CO[C@@H](C)CO YTTFFPATQICAQN-BYPYZUCNSA-N 0.000 description 2
- ICPWFHKNYYRBSZ-VKHMYHEASA-N (2s)-2-methoxypropanoic acid Chemical compound CO[C@@H](C)C(O)=O ICPWFHKNYYRBSZ-VKHMYHEASA-N 0.000 description 2
- XMTKNMQAPNHLJP-QMMMGPOBSA-N (2s)-2-phenylmethoxypropanoyl chloride Chemical compound ClC(=O)[C@H](C)OCC1=CC=CC=C1 XMTKNMQAPNHLJP-QMMMGPOBSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KJZZTCSJZCYCQS-RFVHGSKJSA-N [(2r)-1-phenylpropan-2-yl]-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN[C@H](C)CC1=CC=CC=C1 KJZZTCSJZCYCQS-RFVHGSKJSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 150000004292 cyclic ethers Chemical class 0.000 description 2
- 239000002027 dichloromethane extract Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 2
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 2
- 239000003257 excitatory amino acid Substances 0.000 description 2
- 230000002461 excitatory amino acid Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 238000006902 nitrogenation reaction Methods 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 229910001923 silver oxide Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GVSTYPOYHNVKHY-SCSAIBSYSA-N (2r)-2-methoxybutanoic acid Chemical compound CC[C@@H](OC)C(O)=O GVSTYPOYHNVKHY-SCSAIBSYSA-N 0.000 description 1
- ICPWFHKNYYRBSZ-GSVOUGTGSA-N (2r)-2-methoxypropanoic acid Chemical compound CO[C@H](C)C(O)=O ICPWFHKNYYRBSZ-GSVOUGTGSA-N 0.000 description 1
- BDSSZTXPZHIYHM-SSDOTTSWSA-N (2r)-2-phenoxypropanoyl chloride Chemical compound ClC(=O)[C@@H](C)OC1=CC=CC=C1 BDSSZTXPZHIYHM-SSDOTTSWSA-N 0.000 description 1
- XWAVPOFYNPXXEL-MRVPVSSYSA-N (2r)-2-phenylmethoxypropanoic acid Chemical compound OC(=O)[C@@H](C)OCC1=CC=CC=C1 XWAVPOFYNPXXEL-MRVPVSSYSA-N 0.000 description 1
- IRJCBFDCFXCWGO-BYPYZUCNSA-N (2s)-2-amino-2-(3-oxo-1,2-oxazol-5-yl)acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-BYPYZUCNSA-N 0.000 description 1
- GVSTYPOYHNVKHY-BYPYZUCNSA-N (2s)-2-methoxybutanoic acid Chemical compound CC[C@H](OC)C(O)=O GVSTYPOYHNVKHY-BYPYZUCNSA-N 0.000 description 1
- BDSSZTXPZHIYHM-ZETCQYMHSA-N (2s)-2-phenoxypropanoyl chloride Chemical compound ClC(=O)[C@H](C)OC1=CC=CC=C1 BDSSZTXPZHIYHM-ZETCQYMHSA-N 0.000 description 1
- XWAVPOFYNPXXEL-QMMMGPOBSA-N (2s)-2-phenylmethoxypropanoic acid Chemical compound OC(=O)[C@H](C)OCC1=CC=CC=C1 XWAVPOFYNPXXEL-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000006079 1,1,2-trimethyl-2-propenyl group Chemical group 0.000 description 1
- 125000004893 1,1-dimethylethylamino group Chemical group CC(C)(C)N* 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000006062 1,2-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006035 1,2-dimethyl-2-propenyl group Chemical group 0.000 description 1
- 125000006063 1,2-dimethyl-3-butenyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000006065 1,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006066 1,3-dimethyl-3-butenyl group Chemical group 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- XTIGGAHUZJWQMD-UHFFFAOYSA-N 1-chloro-2-methoxyethane Chemical compound COCCCl XTIGGAHUZJWQMD-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000006067 2,2-dimethyl-3-butenyl group Chemical group 0.000 description 1
- 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006077 2-ethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006078 2-ethyl-3-butenyl group Chemical group 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- YWGZRNXPDONHEM-UHFFFAOYSA-N 2-methoxy-2-methylpropanoyl chloride Chemical compound COC(C)(C)C(Cl)=O YWGZRNXPDONHEM-UHFFFAOYSA-N 0.000 description 1
- NBEMORIANHKPTH-UHFFFAOYSA-N 2-methoxypropanoyl chloride Chemical compound COC(C)C(Cl)=O NBEMORIANHKPTH-UHFFFAOYSA-N 0.000 description 1
- IHRUWHJSVMOZTQ-UHFFFAOYSA-N 2-methoxypropyl 4-methylbenzenesulfonate Chemical compound COC(C)COS(=O)(=O)C1=CC=C(C)C=C1 IHRUWHJSVMOZTQ-UHFFFAOYSA-N 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006049 2-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006053 2-methyl-3-pentenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- WBPAQKQBUKYCJS-ZCFIWIBFSA-N 2-methylpropyl (2r)-2-hydroxypropanoate Chemical compound CC(C)COC(=O)[C@@H](C)O WBPAQKQBUKYCJS-ZCFIWIBFSA-N 0.000 description 1
- 125000004892 2-methylpropylamino group Chemical group CC(CN*)C 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000006050 3-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006054 3-methyl-3-pentenyl group Chemical group 0.000 description 1
- 125000006057 3-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000006051 4-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006058 4-methyl-4-pentenyl group Chemical group 0.000 description 1
- DHELIGKVOGTMGF-UHFFFAOYSA-N 5-chloro-1-phenyltetrazole Chemical compound ClC1=NN=NN1C1=CC=CC=C1 DHELIGKVOGTMGF-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Natural products OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100241859 Mus musculus Oacyl gene Proteins 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 1
- 206010028923 Neonatal asphyxia Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004651 carbonic acid esters Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- NGPGDYLVALNKEG-OLXYHTOASA-N diammonium L-tartrate Chemical class [NH4+].[NH4+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O NGPGDYLVALNKEG-OLXYHTOASA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- YKWNUSJLICDQEO-UHFFFAOYSA-N ethoxyethane;propan-2-ol Chemical compound CC(C)O.CCOCC YKWNUSJLICDQEO-UHFFFAOYSA-N 0.000 description 1
- LZCLXQDLBQLTDK-BYPYZUCNSA-N ethyl (2S)-lactate Chemical compound CCOC(=O)[C@H](C)O LZCLXQDLBQLTDK-BYPYZUCNSA-N 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000006328 iso-butylcarbonyl group Chemical group [H]C([H])([H])C([H])(C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- YNXURHRFIMQACJ-UHFFFAOYSA-N lithium;methanidylbenzene Chemical compound [Li+].[CH2-]C1=CC=CC=C1 YNXURHRFIMQACJ-UHFFFAOYSA-N 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
Benzomorphane derivs. of formula (I) are new. In (I), X = O or S; R1 = 1-8C alkyl, 3-6C alkenyl, 3-6C alkynyl or aryl; R2 = H, 1-8C alkyl, 3-6C alkenyl, 3-6C alkynyl, aryl or aralkyl; R3 = H or 1-6C alkyl; R4 and R5 = each 1-8C alkyl; R6 = 1-8C alkyl or aryl; R7 and R8 = each H, 1-8C alkyl, halogen, OH, 1-8C alkoxy, O-Acyl, CN, NO2, NH2, NH(1-8C alkyl), N(1-8C alkyl)2 (n which the alkyl gps. are opt. different), NH-acyl or N-acyl-(1-8C alkyl).
Description
Benzomorphan derivatives invention relates to new benzomorphan to processes for their preparation and to pharmaceutical compositions.
The present derivatives , their use as According to the present invention we provide compounds of general formula (I): wherein X represents an oxygen or sulphur atom; R1 represents a C^g-alkyl, C3_6-alkenyl, C36alkynyl or aryl group; R2 represents a hydrogen atom or a Cv8-alkyl, alkenyl, C36-alkynyl, aryl or aralkyl group R3 represents a hydrogen atom or a C^-alkyl group; R4 represents a C^g-alkyl group; R5 represents a C^g-alkyl group; R6 represents a C^g-alkyl or aryl group; and R7 and R8, which may be identical or different, - 2 each represent a hydrogen or halogen atom or a C^g-alkyl, -OH, C^g-alkoxy, -O-acyl, -CN, -N02, NH2, -NH(C^g-alkyl), -NH-acyl, -N-acyl(C^g-alkyl), or -N(C^g-alkyl)2 group (wherein the alkyl groups may be identical or different); and all racemic, enantiomeric and diastereomeric forms thereof and mixtures thereof and acid addition salts thereof.
Unless specifically stated otherwise, the general definitions are used in the following sense: C^g-alkyl or C^g-alkyl generally represents a straightchained or branched hydrocarbon radical having 1 to 6 or 8 carbon atoms respectively which may optionally be substituted by one or more halogen atoms - preferably fluorine - which may be identical to one another or different. The following hydrocarbon radicals may be mentioned by way of example: methyl, ethyl, propyl, 1methylethyl (isopropyl), butyl, 1-methylpropyl, 2methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,225 dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1.3- dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3.3- dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,230 trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-lmethylpropyl and 1-ethyl-2-methylpropyl. Unless otherwise stated, lower alkyl groups having 1 to 3 carbon atoms such as methyl, ethyl, propyl or isopropyl are preferred.
Alkenyl in general represents a straight-chained or branched hydrocarbon radical having 3 to 6 carbon atoms - 3 and one or more, preferably one double bond which may optionally be substituted by one halogen atom or several halogen atoms, preferably fluorine, which may be identical to one another or different. Examples include: 2-propenyl (allyl), 2-butenyl, 3-butenyl, 1methyl-2-propenyl, 2-methyl-2-propenyl, 2-pentenyl, 3pentenyl, 4-pentenyl, l-methyl-2-butenyl, 2-methyl-2butenyl, 3-methyl-2-butenyl, l-methyl-3-butenyl, 2methyl-3-butenyl, 3-methyl-3-butenyl, 1,l-dimethyl-210 propenyl, 1,2-dimethyl-2-propenyl, l-ethyl-2-propenyl, 2- hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, l-methyl-2pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4methyl-2-pentenyl, l-methyl-3-pentenyl, 2-methyl-3pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 115 methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4pentenyl, 1,l-dimethyl-2-butenyl, 1,l-dimethyl-3butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2dimethyl-3-butenyl, 2,3-dimethyl-2-butenyl, 2,320 dimethyl-3-butenyl, l-ethyl-2-butenyl, l-ethyl-3butenyl, 2-ethyl-l-butenyl, 2-ethyl-2-butenyl, 2-ethyl3- butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-l-methyl2-propenyl and l-ethyl-2-methyl-2-propenyl. The allyl group is preferred.
Alkynyl in general represents a straight-chained or branched hydrocarbon radical having 3 to 6 carbon atoms and one or more triple bonds. A lower alkynyl radical (propargyl) having 3 carbon atoms and a triple bond which may optionally be substituted by a halogen atom preferably fluorine - or several halogen atoms which may be identical to one another or different is preferred.
Acyl in general represents benzoyl or alkylcarbonyl radicals - such as straight-chained or branched lower alkyl having from 1 to about 6 carbon atoms bound via a carbonyl group, the alkyl radical optionally being - 4 substituted by one or more halogen atoms, which may be identical to one another or different. Alkyl groups having up to 4 carbon atoms are preferred. Examples include: acetyl, trifluoroacetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl and isobutylcarbonyl. The acetyl group is particularly preferred.
Acyloxy denotes an acyl group bound via an oxygen atom, 10 acyl being defined as hereinbefore.
Aryl in general represents an aromatic radical having 6 to 10 carbon atoms - also in combinations, it being possible for the aromatic ring to be substituted by one or more lower alkyl group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or more halogen atom(s) - which are identical to one another or different. The preferred aryl group is phenyl.
Aralkyl in general represents an aryl radical having 7 to 14 carbon atoms which is bonded via an alkylene chain, it being possible for the aromatic ring to be substituted by one or more lower alkyl group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or more halogen atom(s) - which are identical to one another or different. Aralkyl radicals having 1 to 6 carbon atoms in the aliphatic part and 6 to 10 carbon atoms in the aromatic part are preferred. Preferred aralkyl radicals which may be mentioned - unless otherwise stated - are: benzyl, phenethyl and phenylpropyl.
Alkoxy in general represents a straight-chain or branched hydrocarbon radical having 1 to 8 carbon atoms which is bonded via an oxygen atom. A lower alkoxy radical having 1 to 3 carbon atoms is preferred. The methoxy group is particularly preferred. - 5 Unless otherwise stated, amino represents an NH2~function which may optionally be substituted by one or two C^galkyl, aryl or aralkyl groups, either identical or different.
Alkylamino, for example, denotes methylamino, ethylamino, propylamino, 1-methylethylamino, butylamino, 1-raethylpropylamino, 2-methylpropylamino or 1,1dimethylethylamino.
Dialkylamino, for example, denotes dimethylamino, diethylamino, dipropylamino, dibutylamino, di-(lmethylethyl)amino, di-(1-methylpropyl)amino, di-2methylpropylamino, ethylmethylamino or methylpropylamino.
Unless stated otherwise, halogen primarily represents fluorine, chlorine and bromine and, to a lesser degree, iodine.
Compounds according to the present invention which are preferred include compounds of general formula (I) wherein X represents an oxygen or sulphur atom; R1 represents a methyl, ethyl, propyl, isopropyl or phenyl group; R2 represents a methyl, ethyl, propyl, isopropyl, allyl, propargyl, phenyl or benzyl group; R3 represents a hydrogen atom or a CV4-alkyl group; R4 represents a methyl, ethyl, propyl or isopropyl group; - 6 R5 represents a methyl, ethyl, propyl or isopropyl group; R6 represents a methyl, ethyl, propyl, isopropyl 5 or phenyl group; R7 represents a fluorine or chlorine atom or a hydroxy, lower alkyl, lower alkoxy or acyloxy group; and R8 represents a hydrogen atom or a lower alkyl, hydroxy or alkoxy group; and all racemic, enantiomeric and diastereomeric 15 forms thereof and mixtures thereof and acid addition salts thereof.
Compounds according to the present invention which are particularly preferred include compounds of general formula (I) wherein X represents an oxygen atom; R1 represents a methyl or ethyl group; R2 represents a methyl or ethyl group; R3 represents a hydrogen atom; R4 represents a methyl or ethyl group; R5 represents a methyl or ethyl group; R6 represents a methyl or ethyl group; R7 represents a hydroxy, methyl, methoxy or acyloxy group; and - Ί R8 represents a hydrogen atom or a methyl, ethyl, hydroxy or lower alkoxy group; and all racemic, enantiomeric and diastereomeric forms thereof and mixtures thereof and acid addition salts thereof.
Compounds according to the present invention which are more particularly preferred are compounds of general formula (I) wherein X represents an oxygen atom; R1 represents a methyl group; R2 represents a methyl group; R3 represents a hydrogen atom; R4 represents a methyl group; R5 represents a methyl group; R6 represents a methyl group; R7 represents a hydroxy, methyl, methoxy or acetoxy group; and R8 represents a hydrogen atom or a methyl, hydroxy, methoxy or ethoxy group; and all racemic, enantiomeric and diastereomeric forms thereof and mixtures thereof and acid addition salts thereof; especially preferred being those in which the substituents R7 and R8 are in the 2'-position and 3'35 - 8 position respectively and the 2-carbon atom has the Rconfiguration.
The numbering of the positions in the compounds of formula (I) is as follows: The present invention relates to the individual isomers, mixtures thereof and the corresponding physiologically suitable acid addition salts of the compounds of formula (I) with inorganic or organic acids. Examples of preferred salts are those with hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, lactic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid or benzoic acid. 1. Methods of synthesis The compounds according to the present invention may be prepared by a variety of processes.
According to a further aspect of the present invention we provide a process for the preparation of a compound of general formula (I) as hereinbefore defined wherein either a) a compound of general formula (2) (wherein R4, R5 - 9 and R6 are as defined hereinbefore and R9 and R10 are either as defined hereinbefore for R7 and R8 or represent groups which can be converted into the latter in a known manner) is reacted with a carboxylic acid derivative of general formula (4) (wherein Y represents a leaving group, capable of being substituted by a secondary amino group, and R1, R2, R3 and X are as defined hereinbefore) and the resulting acid amide of formula (3) is subsequently reduced to obtain the amine of general formula (6) and, where necessary, the substituents R9 and R10 as defined above are converted into R7 and R8 as defined hereinbefore, and the compound of formula (I) thereby obtained is isolated; or b) a compound of general formula (2) R1 Ζ-0Η2-/.χ/' R3 (5) R2 2 (wherein R4, R5, R6, R9 and R10 are as defined above in a)) is reacted with an alkylating agent of general formula (5) (wherein Z represents a leaving group, which can be substituted by a secondary amino group, and R1, R2, R3 and X are as defined hereinbefore), to obtain the tertiary amine of / R Fc and, where necessary, the substituents R9 and R10 as defined above are converted into R7 and R8 as defined in claim 1, and the compound of formula (I) thereby obtained is isolated.
Thus the compounds of formula (I) according to the present invention may be prepared according to the following reaction scheme: _n-h Rio / R9xC=/'r6 r9A=/ (2) - 11 The type 2 benzomorphan derivatives used as starting materials in this scheme are either prepared according to the prior art [DE-A 20 27 077, CA 24 (1971) 125482x; EP-B 4960, CA 93 (1980) 4941 f] or are prepared as described in the Examples given hereinafter.
The substituents R9 and R10 are either identical to the 10 desired substituents R7 and R8 or are converted into them in a later stage of synthesis. 1.1a One way of introducing a desired substituent at the 15 amino function of the benzomorphan nitrogen is to carry out acylation with a suitably activated carboxylic acid derivative. Corresponding carboxylic acid derivatives of type 4 are known from the prior art or are easily obtainable by current methods of synthesis.
Preferred leaving groups for the compounds of type 4 include, for example, halogen, hydroxy, 0C(0)alkyl, Oacyl, OSO2alkyl and OSO2aryl.
For the acylation itself there are again a number of methods to choose from [C. Ferri, Reaktionen der organischen Synthese, Georg Thieme Verlag Stuttgart, 1978, p. 222 ff. and loc. cit. J. March, Advanced Organic Chemistry, 3rd Ed., John Wiley and Sons, New - 12 York 1985, p. 370 ff and loc. cit.; R.C. Larock, Comprehensive Organic Transformations - A Guide to Functional Group Preparations, VCH Verlagsgesellschaft, D-6940 Weinheim 1989, p. 963 ff and loc. cit.], the preferred method being reactions with carboxylic acid halides [A.L.J. Beckwith in J. Zabicki, The Chemistry of Amides, Interscience, New York 1970 p. 73] in a solvent which is substantially inert under the reaction conditions prevailing, optionally in the presence of acid-binding agents. The inert solvents used are generally organic solvents which do not change under the reaction conditions used, such as hydrocarbons - e.g. benzene, toluene or xylene - or petroleum fractions or ethers - e.g. diethylether, glycoldimethylether (glyme), diglycoldimethylether - or cyclic ethers - e.g. tetrahydrofuran or dioxane - or halohydrocarbon - e.g. carbon tetrachloride, chloroform or dichloromethane.
The preparation of the desired carboxylic acid halides is known from the prior art [Houben-Weyl, Methoden der organischen Chemie, Volume VIII and Volume E5, Georg Thieme Verlag, Stuttgart, 1952 and 1985] where they are not commercially obtainable. Conveniently, the benzomorphan derivative of type 2 is preferably reacted in halogenated hydrocarbons, especially in dichloromethane, and in the presence of tertiary amines, such as triethylamine, with the desired acid halide, more especially with the desired acid chloride.
However, it is also possible to carry out the reaction 30 according to the so-called Schotten-Baumann Variant - in water or in an aqueous alcohol in the presence of alkali metal hydroxides or alkali metal carbonates [see for example Organikum, Autorenkollektiv, VEB Deutscher Verlag der Wissenschaften, 17th Edition, Berlin 1988 p. 407]. Depending on the educts used it has also proved particularly advantageous to carry out the acylation according to the Einhorn variant, in which - 13 pyridine is used both as an acid-binding agent and as a reaction medium.
In addition, there is the possibility of carrying out 5 the reaction of acylation with the free carboxylic acid [see for example A.L.J. Beckwith in J. Zabicki, The Chemistry of Amides, Interscience, New York 1970, p. 105 ff; J.A. Mitchell and E.E. Reid, J. Am. Chem. Soc. (1931) 1879]. It may also prove appropriate to use a mixed anhydride, e.g. with a carbonic acid ester, instead of the free carboxylic acid [C. Ferri, Reaktionen der organischen Synhtese, Georg Thieme Verlag, Stuttgart 1978, p. 222 and loc. cit.; A.L.J. Beckwith in J. Zabicki, The Chemistry of Amides, Interscience, New York 1970, p. 86; J. March, Advanced Organic Chemistry, 3rd Ed., John Wiley and Sons, New York 1985, p. 371 and loc. cit., R.C. Larock, Comprehensive Organic Transformations, VCH Publishers, D-6940 Weinheim 1989, p. 981 and loc. cit.].
In the preferred acylation with carboxylic acid halides, especially carboxylic acid chlorides, the reaction temperature may vary within wide limits, the lower limit being set by excessively slow reaction speeds whilst the upper limit is set by the proliferation of undesirable secondary reactions. Reaction temperatures in the range from -50°C to 150°C, preferably from O’C to 75°C, have proved suitable. The work is conveniently done with a slight excess of the acylating agent in the presence of an acid binding agent (present in a somewhat larger excess) to ensure that the educts are reacted as completely as possible. 1.1b In order to obtain the desired amine of type 6, it is necessary to reduce the acid amide 3 in the subsequent reaction step. - 14 Reductions of acid amides of this kind are known from the prior art and may be carried out by electrolytic reduction, by reduction with alkali metals and by catalytic reduction [R. Schroter in Houben-Weyl, Methoden der organischen Chemie, Volume XI/1, Georg Thieme Verlag, Stuttgart 1957, p. 574] or with diborane or borane derivatives [J. Fuhrhop and G. Penzlin, Organic Synthesis - Concepts - Methods - Starting Materials, VCH-Verlagsgesellschaft, Weinheim 1986, p. 90].
It is preferred to carry out the reduction with complex hydrides such as alkali metal borohydrides or alkali aluminium hydrides with suitable derivatives thereof, optionally in the presence of a catalyst [N.G. Gaylord, Reduction with Complex Metal Hydrides, Wiley New York 1965; A. Hajos, Complex Hydrides, Elsevier New York 1979; V. Ba2ant, M. Capka, M. Cerny, V. Chvalovsky, K. Kochloefl, M. Kraus und J. Malek, Tetrahedron Lett. 9 20 (1968) 3303], lithium aluminium hydride being particularly preferred.
Suitable reaction media are all the inert organic solvents which do not change under the reaction conditions specified. These preferably include ethers such as diethylether, diisopropylether, tert.butylmethylether, di-n-butylether, glycoldimethylether (glyme), diglycoldimethylether (diglyme), cyclic ethers such as dioxane and, particularly preferably, tetrahydrofuran, the choice of solvent being guided, inter alia, by the particular reducing agent used.
It is generally advantageous to allow these reductions to proceed in the presence of an excess of the reducing agent, which preferably takes the form of one of the above-mentioned complex hydrides, particularly lithium alanate, in a range from 5 to 100%, preferably in the IE 922144 " - 15 range from 10 to 50%.
The reactants are usually added whilst cooling with ice or at ambient temperature and then heated to temperatures in the region of 150°C, preferably up to 75 °C, depending on the reactivity of the educts. 1.2 Another possible method of preparing benzomorphan derivatives of type 6 is to react the benzomorphan derivative 2 with suitable alkylating agents of type 5, in which Z in formula 5 represents a leaving group which leaves during the alkylation. Preferred leaving groups include, for example, halogen, such as Cl, Br and I, or O-SO2-aryl, such as tosylate, or an alkylsulphonate O-SO2~alkyl, such as methanesulphonate, or halomethanesulphonate or sulphate. Corresponding alkylating reagents are either commercially obtainable or may be prepared by methods known in the art.
Suitable solvents include all inert solvents which remain substantially unchanged under the reaction conditions specified and which, because they are not themselves reactive components, cannot have a negative influence on the course of the reaction. Examples are alcohols, such as methanol, ethanol, propanol or isopropanol, or ethers, such as diethylether, di-nbutyl-ether, tert.butylmethylether, glycoldimethylether (glyme), diethyleneglycoldimethylether (diglyme), tetrahydrofuran and dioxane - or ketones, such as methylethyl ketone or acetone, or acid amides, such as hexamethyl phosphoric acid triamide or dimethylformamide.
It is also possible to use mixtures of the abovementioned solvents. Tetrahydrofuran or dimethylformamide or mixtures of these two solvents are - 16 particularly preferred. The reaction is preferably carried out in the presence of acid-binding agents such as alkali or alkaline earth metal carbonates or hydrogen carbonates.
The reaction temperature may vary within wide limits in the course of the reaction, these limits being set by too slow a reaction rate, at the bottom of the scale, for practical purposes, and by a prevalence of side reactions, at the top of the scale. Suitable reaction temperatures fall within the range from O’C to 150°C and preferably from 50°C to 100°C. 1.3 The conversion of R9 and/or R10 into R7 and R8, respectively, which may be necessary, involves a number of different reactions, which cannot be illustrated in a single scheme. Such conversion reactions are described hereinafter in the corresponding Examples. 2. Pharmacological Characterisation It is known that after systemic administration of glutamate, neurones are destroyed in mouse brains [S.M.
Rothman and T.W. Olney, Trends in Neurosciences 10 (1987) 299]. This finding leads one to conclude, inter alia. that glutamate plays a part in neurodegenerative diseases [R. Schwarcz and B. Meldrum, The Lancet .11 (1985) 140].
In addition, substances such as quisqualic acid, cainic acid, ibotenic acid, glutamic acid and N-methyl-Daspartic acid (NMDA) are known as exogenous or endogenous neurotoxins. In terms of their neurotoxicity these substances have a selective effect on individual types of cells, which means that loss of function can be induced in animals by specific brain lesions. This loss - 17 of function is comparable with that which occurs in connection with epilepsy and other neurodegenerative diseases, such as Huntington's chorea and Alzheimer's disease.
Furthermore, tests carried out in vivo and in vitro have shown that the cell damage and loss of function occurring in the brain as a result of hypoglycaemia, hypoxia, anoxia and ischaemia are due to an increased synaptic activity, the glutamatergic synapse being particularly significant. Substances and ions which inhibit the activity of the glutamate receptor and the ion channel connected to this receptor - such as competitive and non-competitive antagonists of excitatory amino acids as well as magnesium ions (Mg2*) protect the brain cells from hypoxic or ischaemic damage. These findings show that the glutamate receptor plays an important part in mediating ischaemic damage.
Biochemical and electrophysiological studies show that the receptor ion channel is highly sensitive to fluctuations in the magnesium concentration. If there is a fall in the magnesium concentration, spontaneous epileptic discharges are caused in the hippocampus, which can be inhibited by antagonists of excitatory amino acids.
Surprisingly, it has now been found that benzomorphan derivatives of general formula (I) block the NMDA30 channel and have a neuroprotective activity.
The preparation of these benzomorphan derivatives is known from German Patent 21 05 743 and German Offenlegungsschrift 28 28 039 and from the literature [H. Merz and K. Stockhaus, J. Med. Chem. 22 (1979) 1475]. It is also already known that compounds of this kind have an analgesic effect and can be used - 18 therapeutically as non-addictive analgesics as well as antitussives (German Patent 21 05 743).
The hippocampal section is used as a test system for 5 demonstrating the NMDA-antagonistic activity of the benzomorphan derivatives according to the present invention. The Schaffer collaterals of the hippocampal section in an infusion chamber are stimulated by means of microelectrodes and the total potentials occurring are derived extracellularly at the pyramidal cells of the CAI-region [H.L. Haas, Schaerer and M. Vosmansky, J. Neuroscience Meth. 1. (1979) 323].
The neuroprotective effect of the benzomorphan derivatives which fall within the scope of general formula (I) was also demonstrated in relation to protein synthesis and the liberation of neurotransmitters in the hippocampal section.
Receptor binding tests also show that the benzomorphan derivatives disclosed are non-competitive glutamate receptor antagonists.
Furthermore, the neuroprotective activity of the benzomorphan derivatives of general formula (I) was tested on the mouse - in vivo - by inhibiting the lethality induced by N-methyl-D-aspartic acid [J.D. Leander et al., Brain Research 448 (1988) 115] and by inhibiting the ischaemia-induced neuronal cell death in the mouse and gerbil.
These results, therefore, indicate that the compounds according to the present invention i.e. the benzomorphan derivatives of general formula (I) are suitable for the prevention, treatment and repair of neurodegenerative diseases and conditions, epilepsy, cerebral ischaemia of various origins and damage caused therefrom. These - 19 include, for example: the epileptic state, hypoglycaemia, hypoxia, anoxia, brain trauma, brain oedema, amyotropic lateral sclerosis, Huntington's disease, Alzheimer's disease, hypotonia, cardiac infarct, cerebral stroke and perinatal asphyxia. 3. Formulations According to a yet further aspect of the present invention there are provided pharmaceutical compositions comprising as active ingredient at least one compound of formula (I), as hereinbefore defined, in the form of a single enantiomer or diastereoisomer or mixtures thereof, or a physiologically acceptable acid addition salt thereof in association with one or more pharmaceutically acceptable carriers, diluents or excipients .
The benzomorphan derivatives of general formula (I) and the acid addition salts thereof with pharmacologically acceptable acids may be converted in known manner into the usual formulations such as plain or coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert pharmaceutically acceptable carriers or solvents. The proportion of pharmaceutically active compounds should be within the range from 0.5 to 90 wt.-% of the total composition, i.e. in amounts which are sufficient to achieve the dosage range specified below.
The formulations are prepared, for example, by diluting the active substances with solvents and/or carriers, optionally using emulsifiers and/or dispersing agents, whilst if water is used as the diluent, for example, organic solvents may be used as solubilisers or auxiliary solvents. - 20 Examples of excipients include water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silica and silicates), sugars (e.g. glucose, lactose and fructose), emulsifiers (e.g. lignin, sulphite waste lyse, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium laurylsulphate).
The preparations are administered in conventional manner, preferably by parenteral route, particularly by infusion, and intravenously. In the case of oral administration the tablets may, of course, contain in addition to the above-mentioned carriers additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additional substances such as starch, preferably potato starch, gelatine and the like. In addition, lubricants such as magnesium stearate, sodium laurylsulphate and talc may be used in making the tablets. In the case of aqueous suspensions, the active substances may be combined with various flavour improvers or colourings in addition to the excipients mentioned above.
For parenteral administration, solutions of the active substances may be prepared, using suitable liquid carriers.
The dosage for oral use is from 1 to 300 mg, preferably between 5 and 150 mg.
However, it may in some cases be necessary to deviate from the amounts specified, depending on the body weight - 21 or method of administration, the individual response to the drug, the type of formulation and the time or period of time over which the preparation is administered.
Thus, in some cases, it may be sufficient to use less than the prescribed minimum whereas in other cases the upper limit must be exceeded. If larger quantities are administered it may be advisable to divide them into several smaller doses distributed over the day.
Furthermore, the compounds of general formula (I) or the acid addition salts thereof may also be combined with active substances of other kinds.
According to a yet further feature of the present invention there is provided a method of prevention, treatment or repair of neurogenerative diseases and conditions, of epilepsy, and of cerebral ischaemia of various origins in a subject which comprises administering to said subject an effective amount of a compound of formula (I) as hereinbefore defined or a physiologically acceptable acid addition salt thereof.
The following Examples of formulations serve to further illustrate the present invention.
Tablets 1. The tablet contains the following ingredients: Active substance according to formula I 0.020 parts 30 Stearic acid 0.010 M Dextrose 1.890 II Total 1.920 parts Preparation The substances are mixed together in known manner and the mixture is compressed to form tablets, each weighing - 22 1.92 g and containing 20 mg of active substance.
Ampoule solution Composition Active substance according to formula I 1.0 mg Sodium chloride 45.0 mg Water for injection to 5.0 ml Preparation The active substance is dissolved in water at its own pH or possibly at pH 5.5 to 6.5 and sodium chloride is added to make the solution isotonic. The resulting solution is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 1 mg, 5 mg and 10 mg of active substance.
Suppositories Each suppository contains: Active substance according to formula I Cocoa butter (melting point: 36-37 °C) Carnauba wax 1.0 parts 1200.0 parts .0 parts Preparation The cocoa butter and carnauba wax are melted together.
At 45 °C the active substance is added and the mixture is stirred until fully dispersed. The mixture is poured into suitably sized moulds and the suppositories are suitably packaged. - 23 4. Examples The following non-limiting Examples serve to further illustrate the present invention: In the details which follow, unless otherwise stated, the word ether denotes diethylether. 4.1 Compounds of type (1) - prepared according to process 1.1 4.1.1 Example 1 (-) -(IR,5S,2R)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Acylation 27.8 g (0.12 mol) of (±)-2'-hydroxy-5,9,9-trimethyl-6,720 benzomorphan [DOS 20 27 077; CA 74, 125482x (1971)] are mixed with 278 ml of absolute dichloromethane in the presence of 27.9 g (0.275 mol) of triethylamine and 19.2 g (0.156 mol) of (R)-2-methoxypropionic acid chloride are added, with stirring, within about 30 minutes. The reaction temperature is maintained in the range from 30 to 35 °C. The mixture is then refluxed for one hour. It is then cooled and washed successively with 175 ml of water, 1.75 ml of 2 N hydrochloric acid and twice more with 175 ml of water. After drying with sodium sulphate and filtering off the drying agent the solution is evaporated down in vacuo. at a final temperature of 80°C under a full water jet vacuum. The acylation product of type (3) is obtained as an evaporation residue in a yield of 42.3 g (around 100% of theory). - 24 b) Reduction The acylation product prepared using the process described above is dissolved in 425 ml of absolute tetrahydrofuran. The solution is added dropwise, with stirring and cooling with ice, to a suspension of 9.1 g (0.24 mol) of lithium aluminium hydride (lithium tetrahydridoalanate) in 300 ml of tetrahydrofuran within one hour at 10 to 15 °C. Then the reaction mixture is refluxed for two hours with stirring. 25 ml of water are then added dropwise thereto, whilst cooling in an ice bath and with stirring, and finally, after the addition of a further 70 ml of water and saturated diammonium tartrate solution (890 ml), the mixture is shaken in a separating funnel. The tetrahydrofuran phase separated off is evaporated down in vacuo and the aqueous phase is extracted three times with 175 ml of dichloromethane. The evaporation residue of the tetrahydrofuran phase is dissolved with the dichloromethane extracts and the solution is washed twice with 100 ml of water. After drying with sodium sulphate and removal of the drying agent by filtering, the solution is evaporated down, at a final temperature of 80°C under a full water jet vacuum. A residue remains (37 g, about 100% of theory), which consists of a mixture of the two diastereomeric compounds expected. In the thin layer chromatograph (TLC) these diastereomers show Rf values of 0.42 and 0.51 (silica gel 60, chloroform-methanol-conc. ammonia 95:5:0.1).
The diastereomers can be separated by crystallisation of the hydrochlorides. To do this, the basic mixture is dissolved in 120 ml of absolute ethanol and the solution is acidified with hydrochloric acid (12 ml 32% hydrochloric acid). The title compound (Rf = 0.42) crystallises immediately, is cooled (ice bath), suction filtered, washed with ice cold ethanol (40 ml) in - 25 batches and is dried, at a final temperature of 80 °C, until a constant weight is achieved. The yield is 15.0 g (73.5% of the maximum amount theoretically obtainable). The substance melts at 264 °C with decomposition and has a specific optical rotation of [a]25= -116.9° (c = 1, CHjOH) . A sample recrystallised from a mixture of methanol and diethylether melts at an unchanged melting point of 264 °C (decomp.) and has a specific rotation of [a]25 = -118.6° (c = 1, CHjOH) . 4.1.2 Example 2 ( + ) -(IS,5R,2R)—2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The mother liquor obtained in the process according to Example 1 contains predominantly the diastereomer with an Rf value of 0.51. It is evaporated down and the residue (25 g) is heated to reflux temperature with 40 ml of isopropanol for one hour with stirring. The crystal suspension thus obtained is left to stand at ambient temperature for about 12 hours, then suction filtered and washed in batches with a little cold isopropanol. The crystals consist mainly of the title compound together with residues of the diastereomer (Example 1). The title compound is converted into the free base form and purified by column chromatography.
For this purpose, the crystals are shaken with water (75 ml), dichloromethane (75 ml) and excess cone. ammonia (25% strength, 6 ml). After separation of the phases the aqueous layer is extracted once more with 25 ml of dichloromethane. The combined dichloromethane extracts are washed twice with 25 ml of water, then dried with sodium sulphate and, after removal of the drying agent by filtration, evaporated down at a final temperature of 80°C under a full water jet vacuum. The residue (15.4 g) is purified by column chromatography on - 26 2 kg of silica gel (MN K 60, 230-400 mesh ASTM made by Macherey and Nagel) using dichloromethane-methanol-conc. ammonia 95:5:0.1 as eluant. The fractions containing the pure substance yield a residue (6.8 g) after evaporation, consisting of the base of the title compound. The residue is dissolved with 14 ml of absolute ethanol and the solution is acidified with 10 ml of 2.5 N ethanolic hydrochloric acid. After the addition of diethylether until the turbidity is just constant, the title compound crystallises out. The mixture is left to stand in the refrigerator for about 12 hours and then suction filtered and washed first with an methanol-ether mixture 1:2 and then with ether.
After drying, finally at 80°C, 6.4 g of the title compound are obtained (31.4% of the maximum amount theoretically obtainable) with a melting point of 236°C (decomp.) and a specific rotation of [a]p5= +88.0° (c = l, ch3oh). 4.1.3 Example 3 ( + ) - (IS ,5R,2S)-21-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 9.25 g (0.040 mol) of (±)-2'-hydroxy5, 9,9-trimethyl-6,7-benzomorphan and 6.37 g (0.052 mol) of (S)-2-methoxypropionic acid chloride, the title compound is obtained analogously to Example 1 in a yield of 5.1 g (75.0% of theory) with an Rf value of 0.42, a melting point of 270°C (decomp.) and a specific rotation of [α]*5 = +117° (c = 1, CH3OH) . - 27 4.1.4 Example 4 (-)-(IR,5S,2S)-2'-hydroxy-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from the mother liquor obtained in Example 3 the title compound is obtained analogously to Example 2 in a yield of 3.2 g (47.1% of theory) with a melting point of 235 °C (decomp.) and a specific rotation of [a]25 = -89.9° (c = 1, CH3OH) . 4.1.5 Example 5 (-)-(IR,5S,2R)-21-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride If instead of the racemic starting compound 2.31 g (0.010 mol) of the enantiomerically pure (-)-2'-hydroxy5, 9 , 9-trimethyl-6 , 7-benzomorphan are reacted analogously to Example 1 with 1.60 g (0.013 mol) of (R)-2methoxypropionic acid chloride, instead of a mixture of the diastereomeric bases the sterically pure base of the title compound will first be obtained and from this the hydrochloride is obtained in a yield of 3.0 g (88.4% of theory) with a melting point of 264 °C (decomp.) and a specific rotation of [α]2θ= -117.5° (c = 1, CH3OH) . 4.1.6 Example 6 (-) -(IR,5S,2S)-2’-hydroxy-2-(2-methoxy30 propyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride If the synthesis described in Example 5 is carried out with (S)-2-methoxypropionic acid, the title compound is obtained in a yield of 2.9 g (85.3% of theory) with a melting point of 235°C (decomp.) and a specific rotation Of [a]25 = -89.7° (c = 1, CH3OH) . - 28 4.1.7 Example 7 (-)-(IR,5S,2R)— 2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 4.62 g (0.020 mol) of (-)-2'-hydroxy5, 9 , 9-trimethyl-6 , 7-benzomorphan and 3.20 g (0.026 mol) of (R/S)-2-methoxypropionic acid chloride, there is obtained analogously to Example 1 a mixture of the expected diastereomeric bases which are separated by column chromatography analogously to Example 2. The slower running substance (Rf = 0.42) is crystallised as the hydrochloride as described therein. The title compound is obtained in a yield of 2.1 g (61.8% of theory) with a melting point of 264 °C (decomp.) and a specific rotation of [a]25 = -117.9° (c = 1, CH3OH) . 4.1.8 Example 8 (-) -(IR,2S,2S)-2’-hydroxy-2-(2-methoxy20 propyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from the faster running substance (Rf = 0.51) separated in Example 7, the title compound is obtained, after conversion into the hydrochloride analogously to Example 2, in a yield of 2.2 g (64.7% of theory) with a melting point of 235°C (decomp.) and a specific rotation of [a]25 = -88.6°C (c = 1, CHjOH) . 4.1.9 Example 9 ( + ) -(IS ,5R,2S)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride 2.60 g (0.025 mol) of (S)-2-methoxypropionic acid chloride are stirred in 100 ml of absolute tetrahydrofuran with 4.04 g (0.025 mol) of 1,1'IE 922144 - 29 carbonyldiimidazole for two hours at ambient temperature. After the addition of 4.62 g (0.020 mol) of ( + )-2'-hydroxy-5,9,9-trimethyl-6,7-benzomorphan the mixture is stirred for a further two days at ambient temperature. It is then evaporated down, the residue is taken up in 75 ml of dichloromethane and washed successively with 2 N HCl and twice with water. After separation the organic phase is dried with sodium sulphate and after the drying agent has been filtered off, the residue is evaporated down in vacuo. finally at 80°C under a full water jet vacuum. The evaporation residue is reduced with lithium aluminium hydride (lithium tetrahydridoalanate) as described in Example 1 and the reaction product is crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 6.9 g (81.3% of theory) with a melting point of 264°C (decomp.) and a specific rotation of [a]25 = +117.4° (c = 1, CH3OH) . 4.1.10 Example 10 (-)-(IR,5S,2R)-9,9-dimethyl-5-ethyl-2'hydroxy-2-(2-methoxypropyl)-6,7-benzomorphan hydrochloride Starting from 1.69 g (0.006 mol) of (±)-9,9-dimethyl-5ethyl-2'-hydroxy-6,7-benzomorphan hydrochloride [DOS 20 27 077; CA 74 . 125482X (1971)], 1.82 g (0.018 mol) of triethylamine and 0.96 g (0.0078 mol) of (R)-2methoxypropionic acid chloride, a mixture of the expected diastereomeric bases (1.7 g) is obtained analogously to Example 1, these bases being separated by column chromatography analogously to Example 2. The slower running substance (0.6 g, Rf = 0.40) is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.6 g (56.6% of theory) with a melting point of 275°C (decomp.) and a specific rotation of [a]25 = -100.5° - 30 (C = 1, CH3OH). 4.1.11 Example 11 (+)-(IS,5R,2R)-9,9-dimethyl-5-ethyl—2 5 hydroxy-2-(2-methoxypropyl)-6,7-benzomorphan hydrochloride The faster running diastereomer (0.7 g, Rf = 0.45) separated by column chromatography in Example 10 is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.23 g (21.7% of theory) with a melting point of 216°C (decomp.) and a specific rotation of [α]θ5 = +62.4° (c = 1, CH3OH) . 4.1.12 Example 12 ( + ) - (IS,5R,2S)-9,9-dimethyl-5-ethyl-2 hydroxy-2-(2-methoxypropyl)-6,7-benzomorphan hydrochloride Starting from 1.69 g (0.006 mol) of (±)-9,9-dimethyl-5ethyl-2'-hydroxy-6,7-benzomorphan hydrochloride, 1.82 g (0.018 mol) of triethylamine and 0..96 g (0.0078 mol) of (S)-2-methoxypropionic acid chloride, a mixture of the expected diastereomeric bases (1.7 g) is obtained analogously to Example 1 and separated by column chromatography analogously to Example 2. The slower running substance (0.6 g, Rf = 0.40) is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.6 g (56.6% of theory) with a melting point of 275°C (decomp.) and a specific rotation of [a]&5 = +102.5° (c = 1, CH30H) . - 31 4.1.13 Example 13 (-) - (IR,5S,2S)-9,9-dimethyl-5-ethyl-2'hydroxy-2-(2-methoxypropyl)-6,7-benzomorphan hydrochloride The faster running diastereomer (0.6 g, Rf = 0.45) separated by column chromatography according to Example 12 is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.65 g (61.2% of theory) with a melting point of 219 °C (decomp.) and a specific rotation of [a]25 = -67.6° (c = 1, CHjOH) . 4.1.14 Example 14 (-)-9,9-dimethyl-2'-hydroxy-2-((R)-2methoxypropyl)-5-phenyl-6,7-benzomorphan Starting from 1.76 g (6 mMol) of (±)-9,9-dimethyl-21 hydroxy-5-phenyl-6,7-benzomorphan [EP-B-4960; CA 93, 4941f (1980)] and 0.96 g (7.8 mMol) of (R)-2methoxypropionic acid chloride, a mixture of the expected diastereomeric bases (2.1 g) is obtained analogously to Example 1 with Revalues of 0.50 and 0.55 (cf. Example 2). The mixture is crystallised out in the form of the hydrochlorides (2.4 g) analogously to Example 2 and converted back into the corresponding free bases (evaporation residue 1.8 g). This base residue is recrystallised from 6 ml of ethyl acetate and 18 ml of petroleum ether (80°C). Then the title compound is obtained in a yield of 0.72 g (65.5% of theory) with a melting point of 202 °C, an Rf value of 0.50 and a specific rotation of [a]25 = -24.4 ° (c = 1, CH3OH) . - 32 4.1.15 Example 15 (+)-9,9-dimethyl-21-hydroxy-2-((R)-2-methoxypropyl)-5-phenyl-6,7-benzomorphan hydrochloride The mother liquor (ethyl acetate/petroleum ether) obtained during crystallisation according to Example 13 is evaporated down. The residue (1.2 g) is dissolved in 5 ml of ethanol and the solution is acidified with 2.5 N ethanolic hydrochloric acid. After the addition of diethylether until turbidity is beginning, hydrochloride (0.4 g) crystallises out as a contaminated crude product. The mother liquor contains the pure title compound which, after evaporation, is isolated as a residue: yield: 0.75 g (62.0% of theory), melting point 168°C (decomp.), Rf = 0.55, specific rotation [a] θ5 +11.6° (c = 1, CHjOH). 4.1.16 Example 16 (-) -(IR,5S,2R)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Starting compound The (±)-3'-hydroxy-5,9,9-trimethyl-6,7-benzomorphan required here and in other Examples is not known from the prior art. It may be prepared, for example, using the method of synthesis given for the known 21-hydroxy30 isomer [DOS 20 27 077,; CA 74, (1971), 125482X], using m-methoxybenzyllithium instead of p-methoxybenzyllithium. When cyclisation is carried out to obtain the benzomorphan system, two isomeric compounds are obtained in the latter case which are further reacted in the form of a mixture. The mixture of 1'-hydroxy- and 3'hydroxy-5,9,9-trimethyl-6,7-benzomorphan obtained finally is separated by flash column chromatography on - 33 100 times the quantity of silica gel (MN K 60, 230-400 mesh ASTM, made by Macherey and Nagel) using a mixture of ethyl acetate/methanol/conc. ammonia 80:20:5 as eluant. The (±)-11-hydroxy-5,9,9-trimethyl-6,75 benzomorphan (Rf = 0.20) and the (±)-3'-hydroxy-5,9,9trimethyl-6,7-benzomorphan (Rf = 0.14) are obtained in a ratio of 1:2 in the form of viscous oils (Rf values: TLC, silica gel 60, using the eluant mentioned above). b) Reaction to obtain the title compound Starting from 2.31 g (0.010 mol) of (+)-3'-hydroxy5, 9 , 9-trimethyl-6 , 7-benzomorphan and 1.6 g (0.013 mol) of (R)-2-methoxypropionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1 which are separated by column chromatography on 100 times the quantity of silica gel analogously to Example 2. The slower running substance (Rf = 0.65) is crystallised out as the hydrochloride, as described therein. The title compound is obtained in a yield of 0.86 g (50.6%) with a melting point of 240 to 242 °C (decomp.) and a specific rotation of [a]25 = -90.9° (c = 1, CH3OH) . 4.1.17 Example 17 ( + ) - (IS ,5R,2R)-3'-hydroxy-2-(2-methoxypropyl) -5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf = 0.74) separated in Example 16 is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 1.28 g (75.3% of theory) with a melting point of 250-251°C and a specific rotation of [a]25 = +57.1° (c = 1, CH3OH) . - 34 4.1.18 Example 18 ( + ) -(IS ,5R,2S)-3'-hydroxy-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 2.31 g (0.010 mol) of (±)-3'-hydroxy5, 9,9-trimethyl-6,7-benzomorphan (see Example 16) and 1.60 g (0.013 mol) of (S)-2-methoxypropionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1, which are purified by chromatography analogously to Example 2 on 100 times the amount of silica gel. The slower running substance (Rf = 0.65) is crystallised as the hydrochloride as described therein. The title compound is obtained in a yield of 0.57 g (33.4% of theory) with a melting point of 239 to 240 °C (decomp.) and a specific rotation of [a]25 = +90.7 ° (c = 1, CHjOH) . 4.1.19 Example 19 (-)-(IR,5S,2S)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf = 0.74) separated in Example 18 is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.67 g (39.2% of theory) with a melting point of 250-251°C (decomp.) and a specific rotation of [a]25 = -56.5° (c = 1, CHjOH). 4.1.20 Example 20 (-) -(IR,5R,2R)-11-hydroxy-2-(2-methoxypropyl) -5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 2.31 g (0.010 mol) of (±)-1’-hydroxy5, 9,9-trimethyl-6,7-benzomorphan (see Example 16) and - 35 1.60 g of (R)-2-methoxypropionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1 which are separated analogously to Example 2 on 100 times the amount of silica gel. The slower running substance (Rf = 0.52) is crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.70 g (41.2% of theory) with a melting point of 128-135°C (decomp.) and a specific rotation of [a]25 = -100.5° (c = 1, CH3OH) . 4.1.21 Example 21 ( + ) -(IS,5S,2R)-11-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf = 0.56) separated off in Example 20 is crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.40 g (23.6% of theory) with a melting point of 88 to 89°C (decomp.) and a specific rotation of [a]25 = 50.4 ° (c = 1, CH3OH) . 4.1.22 Example 22 ( + ) - (IS,5S,2S)-1’-hydroxy-2-(2-methoxy25 propyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 2.31 g (0.010 mol) of (±)-1'-hydroxy5, 9 , 9-trimethyl-6 , 7-benzomorphan (see Example 16) and 1.60 g (0.013 mol) of (S)-2-methoxy-propionic acid chloride a mixture of the expected diastereomeric bases is obtained analogously to Example 1 which are separated on 100 times the amount of silica gel in accordance with Example 2. The slower running substance (Rf = 0.52) is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.63 g (36.8% of theory) with a melting point of 85 to - 36 90°C and a specific rotation of [α]θ5 = +96.2° (c = 1, CH3OH) . 4.1.23 Example 23 (-)-(IR,5R,2S)-1'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf = 0.56) separated in 10 Example 22 is crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.50 g (29.4% of theory) with a melting point of 90 to 91°C (decomp.) and a specific rotation of [α]θ5 = -64.0° (c = 1, CH3OH) . 4.1.24 Example 24 (-) - (IR, 5S, 2 R) -4 1-hydroxy-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The preparation of (±)-4'-hydroxy-5,9,9-trimethyl-6,7benzomorphan needed here and in other Examples is not known from the prior art. It may, for example, be prepared by the method of synthesis known from the prior art for the known 2'-hydroxy-isomer [DOS 20 27 077, CA 74. 125482x (1971)] by using o-methoxybenzyllithium instead of p-methoxybenzyllithium. The desired compound crystallises as a base from isopropanol-petroleum ether with a melting point of 227 °C. In thin layer chromatography (silica gel 60, chloroform/methanol/conc. ammonia 65:35:3) it may be given an Rf value of 0.20. b) Reaction to obtain the title compound Starting from 2.31 g (0.010 mol) of (±)-4'-hydroxyIE 922144 -375,9,9-trimethyl-6,7-benzomorphan and 1.60 g (0.01 mol) of (R)-2-methoxypropionic acid chloride, a mixture of the expected bases (3.0 g) is obtained analogously to Example 1, which are separated analogously to Example 2 by column chromatography on 450 g of silica gel. 0.9 g of the slower running compound (Rf = 0.34) and 1.3 g of the faster running compound (Rf = 0.43) are obtained.
The former is crystallised as the hydrochloride as in Example 2. The title compound is thus obtained in a yield of 0.95 g (55.9% of theory) with a melting point of 263 °C (decomp.) and the specific rotation of [a]p5 = -86.9° (c = CH3OH) . 4.1.25 Example 25 ( + ) -(IS,5R,2R)—41-hydroxy-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running compound (Rf = 0.43) separated in Example 24 is crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 1.23 g (72.4% of theory) with a melting point of 258 °C (decomp.) and a specific rotation of (a]75= +51.7°, (c = 1, CH3OH) . 4.1.26 Example 26 ( + ) - (IS ,5R,2S)-41-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6, 7-benzomorphan hydrochloride Starting from 2.31 g (0.010 mol) of (±)-4 *-hydroxy5, 9,9-trimethyl-6,7-benzomorphan (see Example 24) and 1.60 g (0.013 mol) of (S)-2-methoxypropionic acid chloride, a mixture of the expected diastereomeric bases (3.1 g) is obtained which are separated by column chromatography on 450 g of silica gel analogously to Example 2. 1.0 g of the slower running compound (Rf = - 38 0.34) and 1.2 g of the faster running compound are obtained. The former is crystallised in the form of the hydrochloride analogously to Example 2 and yields the title compound in a yield of 1.15 g (67.7%) with a melting point of 260°C (decomp.) and a specific rotation of [a]25 * * * * 30 * * * * 35 = -51.2° (c = 1, CH3OH) . 4.1.27 Example 27 (-) -(IR,5S,2S)-4 '-hydroxy-2-(2-methoxy10 propyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf = 0.43) separated in Example 26 is crystallised as the hydrochloride analogously to Example 2 and yields the title compound in a yield of 0.95 g (55.9% of theory) with a melting point of 261°C (decomp.) and a specific rotation of [a]25 = +86.1°, (c = 1, CH3OH) . 4.1.28 Example 28 (-) — (IR, 5S , 2 R) — 2'-methoxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan methanesulphonate Starting from 2.45 g (0.010 mol) of (-)-21-methoxy5,9,9—trimethyl—6,7-benzomorphan [DOS 20 27 077; CA 125482X (1971)] and 1.35 g (0.011 mol) of (R)-2-methoxypropionic acid chloride, the sterically uniform title compound is obtained analogously to Example 1 in the form of the free base (2.3 g). This is dissolved in ml of absolute ethanol. After acidification with methanesulphonic acid the solution obtained is combined with diethylether until turbidity is just beginning.
Whilst the methanesulphonate is crystallising, the same amount of ether is gradually added once more with stirring. Then the reaction mixture is cooled for 4 hours with an ice bath, suction filtered, then washed - 39 first with a 1:2 mixture of ethanol and ether and then with ether on its own. After drying, finally at 80°C, the title compound is obtained in a yield of 3.3 g (79.8% of theory) with a melting point of 165-166°C (decomp.) and a specific rotation of [a]25 = -92.4 ° (c = 1, CH3OH). 4.1.29 Example 29 (+)-(1S,5R,2S)-2'-methoxy-2-(2-methoxy10 propyl)-5,9,9-trimethyl-6,7-benzomorphan methanesulphonate Starting from 2.45 g (0.010 mol) of (+)-2’-methoxy5,9,9-trimethyl-6,7-benzomorphan [DOS 20 27 077; CA 74, 125482X (1971)] and 1.35 g (0.011 mol) of (S)-2methoxypropionic acid chloride, the title compound is obtained analogously to Example 28 in a yield of 3.1 g (75.0% of theory) with a melting point of 165-167°C (decomp.) and a specific rotation of [a]25 = +92.3° (c = 1, CHjOH) . 4.1.30 Example 30 (-) - (IR,5S,2R)-2-(2-methoxypropyl)-5,9,9trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The preparation of (±)-5,9,9-trimethyl-6,7-benzomorphan required here and in other Examples is not known from the prior art. It may be prepared, for example, using the method of synthesis given for the known 2’-hydroxy derivative [DOS 20 27 077; CA 74 (1971) 125482X], using benzyllithium instead of p-methoxybenzyllithium. The desired compound crystallises as a hydrobromide from an isopropanol-ether mixture with a melting point of 259 °C (decomposition). - 40 b) Reaction to obtain the title compound Starting from 2.96 g (0.010 mol) of (±)-5,9,9-trimethyl6,7-benzomorphan and 1.35 g (0.011 mol) of (R)-25 methoxypropionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1. These are separated according to Example 2 by column chromatography on 150 times the amount of silica gel. The slower running substance (Rf = 0.63) is crystallised as the hydrochloride, as described therein. The title compound is obtained in a yield of 1.3 g (76.5% of theory) with a melting point of 225°C (decomp.) and a specific rotation of [a]25 = -101.7° (c = 1, CH3OH) . 4.1.31 Example 31 ( + ) -(IS,5R,2R)-2-(2-methoxypropyl)-5,9,9trimethyl-6,7-benzomorphan oxalate The faster running substance (Rf = 0.67) separated in Example 30 is dissolved with 5 ml of ethanol. After acidification with oxalic acid the solution is mixed with diethylether until turbidity is just beginning. During the crystallisation which then sets in, half the original quantity of ether is gradually added and the mixture is left in the refrigerator for about 12 hours. After suction filtering, washing with an ethanol-ether mixture and drying at 80°C, the title compound is obtained in a yield of 1.1 g (60.4% of theory) with a melting point of 135°C (decomp.) and a specific rotation of [a]25= +60.2° (c = 1, CH3OH) . 4.1.32 Example 32 (-) -(IR,5S,2"R)-2-(2-Methoxypropyl)-2',5,9,935 tetramethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound - 41 The (±)-21-5,9,9-tetramethyl-6,7-benzomorphan required here and in other Examples is not known from the prior art. It may, for example, be prepared using the method of synthesis given for the known 21-hydroxy-analogue, using p-methylbenzyllithium instead of pmethoxybenzyllithium. The intermediate product thus obtained is crystallised in the form of the hydrobromide from an isopropyl-diethylether mixture and melts at 227 °C with decomposition. b) Reaction to obtain the title compound Starting from 1.51 g (5 mMol) of (±)-2'-5,9,9tetramethyl-6,7-benzomorphan and 0.68 g (5.5 mMol) of (R)-2-methoxypropionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1, which are crystallised as the hydrochlorides and separated as described therein. The title compound is obtained in a yield of 0.7 g (after recrystallisation 0.4 g = 47.3% of theory) with a melting point of 212°C (decomp.) and a specific rotation of [a]n25= -110.0° (c = 1, CH3OH). 4.1.33 Example 33 (+)-IS,5R,2S)-2-(2-methoxypropyl)-2’-5,9,9trimethyl-6,7-benzomorphan hydrochloride Starting from 1.51 g (5 mMol) of (±)-2'-5,9,9tetramethyl-6,7-benzomorphan and 0.68 g (5.5 mMol) of (S)-2-methoxypropionic acid chloride the title compound is obtained analogously to Example 32 in a yield of 0.4 g (47.3% of theory) with a melting point of 212°C (decomp.) and a specific rotation of [a]25 = +111.8° (c = 1, CHjOH) . - 42 4.1.34 Example 34 (-) -(IR,5S,2R)—21-amino-2-(2-methoxypropyl) 5,9,9-trimethyl-6,7-benzomorphan dihydrochloride a) Preparation of the starting compound The (±)-2'-nitro-5,9,9-trimethyl-6,7-benzomorphan required here and in other Examples is not known from the prior art. It can be prepared for example by nitrogenation of the (±)-5,9,9-trimethyl-6,7benzomorphan (Example 30) analogously to a method described by E.L. May and E.M. Fry [J. Org. Chem. 22 (1957) 1366]. The resulting intermediate compound is crystallised from an ethanol-ether mixture as the hydrochloride, melting at 289°C (decomp.). b) Acylation 2.97 g (0.01 mol) of (±)-2'-nitro-5,9,9-trimethyl-6,7benzomorphan hydrochloride are acylated in the presence of 3.04 g (0.03 mol) of triethylamine analogously to Example 1 with 1.35 g (0.011 mol) of (R)-2methoxypropionic acid chloride. After working up, 3.5 g (about 100% of theory) of the intermediate product of type (3) are obtained. c) Catalytic hydrogenation of the 2'-nitro- to the 2'amino- group 3.5 g of the intermediate product resulting from step b) are dissolved in 70 ml of methanol and hydrogenated in the presence of 0.4 g of palladium on charcoal (Pd content: 5%) at 20°C under a hydrogen pressure of 5 bar.
The uptake of hydrogen ceases after 4 hours, after the calculated amount has been consumed. After the catalyst has been filtered off the reaction mixture is evaporated - 43 down, finally at 80 °C under a total water jet vacuum. Residue: 3.1 g (about 100% of theory). d) Reduction with lithium aluminium hydride 5 The evaporation residue (3.1 g) obtained above is reduced analogously to Example 1 with 1.3 g of lithium aluminium hydride (lithium tetrahydridoalanate). The resulting mixture of the two expected diastereomeric bases (2.7 g) is separated analogously to Example 2 by column chromatography on 500 g of silica gel. The slower running substance (0.7 g, Rf = 0.65) is crystallised as the dihydrochloride analogously to Example 2 (but with two equivalents of hydrochloric acid). The title compound is obtained in a yield of 0.95 g (50.6% of theory) and with a melting point of 260°C (decomp.) and a specific rotation of [a]25 = -93.4 ° (c = 1, CH3OH) . 4.1.35 Example 35 ( + ) - (IS ,5R,2R)-2'-amino-2-(2-methoxypropyl) 5,9,9-trimethyl-6,7-benzomorphan dimethanesulphonate 0.9 g of the faster running substance (Rf = 0.70) separated in Example 34 are crystallised from a mixture of methanol and diethylether analogously to Example 28 (but with 2 equivalents of methanesulphonic acid). The title compound is obtained in a yield of 0.48 g (19.4% of theory) with a melting point of 189 °C (decomp.) and a specific rotation of [a]25 = +55.6° (c = 1, CH3OH) . 4.1.36 Example 36 ( + ) -(IS,5R,2S)-2’-amino-2-(2-methoxypropyl)35 5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 2.97 g (0.01 mol) of (±)-21-nitro-5,9,9922144 -44trimethyl-6,7-benzomorphan hydrochloride, 3.04 g (0.03 mol) of triethylamine and 1.35 g (0.011 mol) of (S)-2-methoxypropionic acid chloride, 3.5 g (around 100% of theory) of the acylation product are obtained which, as described therein, is catalytically hydrogenated (producing 3.2 g of hydrogenation product) and then reduced with lithium aluminium hydride (lithium tetrahydroalanate). The reduction product (2.8 g), consisting of a mixture of the expected diastereomeric bases, is dissolved in 10 ml of isopropanol with heating. Over a period of about 12 hours, as the mixture is left to stand in the refrigerator, the substance which is slower running in chromatography (Rf = 0.65) crystallises as a base (0.75 g = 49.0% of theory) with a melting point of 142 °C. Of this, 0.3 g were crystallised as the dihydrochloride analogously to Example 32. The title compound (0.37 g) is obtained with a melting point of 265°C (decomp.) and a specific rotation of [α]";5 = +92.5° (c = 1, CH3OH) . 4.1.37 Example 37 (-)-(IR,5S,2S)—2'-amino-2-(2-methoxy-propyl)5,9,9-trimethyl-6,7-benzomorphan dihydrochloride The isopropanol mother liquor of Example 34 is evaporated down and the residue (2.0 g) is chromatographed on 300 g of silica gel analogously to Example 2. The faster running diastereomer (1.2 g, Rf = 0.70) together with another 0.3 g of the slower running substance (Rf = 0.65, Example 34) is crystallised as the dihydrochloride analogously to Example 32. The title compound is obtained in a yield of 1.48 g (78.8% of theory) with a melting point of 259°C (decomp.) and a specific rotation of [<*]p5= -68.4° (c = 1, CH3OH) . - 45 4.1.38 Example 38 (±)-2'-hydroxy-2-(2-methoxyisobutyl)-5,9,9trimethyl-6,7-benzomorphan hydrobromide Starting from 1.16 g (0.005 mol) of (±)-21-hydroxy5, 9,9-trimethyl-6,7-benzomorphan and 0.75 g (0.055 mol) of 2-methoxyisobutyric acid chloride, first the base form of the title compound (1.1 g) is obtained analogously to Example 1. This is dissolved in 5 ml of 10 methanol and after acidification with (62%) HBr the solution is mixed with diethylether until turbidity is just setting in. When left to stand for about 12 hours in the refrigerator the title compound crystallises out, is suction filtered, washed with a mixture of ethanol and ether and dried at 80°C. Yield 1.1 g (55.2% of theory), melting point 232 °C (decomp.). A sample recrystallised from methanol-ether mixture melts at 240°C (decomp.). 4.1.39 Example 39 (-) - (IR,5S,2"R)-2'-hydroxy-2-(2-methoxybutyl)5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The (R)-2-methoxy-butyric acid chloride needed in this and other Examples may, for example, be prepared from the known (R)-2-methoxybutyric acid [N.K. Kochetkov, A.M. Likhosherstov and V.N. Kulakov, Tetrahedron 25 (1969) 2313] and thionylchloride at ambient temperature.
The acid chloride remaining after the excess thionylchloride has been removed is used in the next reaction step without any further purification. b) Reaction to obtain the title compound Starting from 3.47 g (0.015 mol) of (±)-2'-hydroxyIE 922144 - 46 5,9,9-trimethyl-6,7-benzomorphan and 2.46 g (0.018 mol) of (R)-2-methoxybutyric acid chloride the title compound is obtained analogously to Example 1 in a yield of 1.8 g (67.8% of theory) with a melting point of 246°C (decomp.) and a specific rotation of [a]25 = -118.4° (c = 1, CH30H) . 4.1.40 Example 40 ( + ) -(IS,5R,2R)-21-hydroxy-2-(2-methoxybutyl) 10 5,9,9-trimethyl-6,7-benzomorphan hydrochloride The mother liquor obtained in Example 39 is evaporated down. From the residue, the title cmpound is obtained analogously to Example 2 in a yield of 1.3 g (48.9% of theory) with a melting point of 228 °C (decomp.) and a specific rotation of [a]25 = +79.9 ° (c = 1, CH3OH) . 4.1.41 Example 41 (-) -(IR,5S,2S)-2'-hydroxy-2-(2-methoxybutyl) 20 5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The (S)-2-methoxybutyric acid chloride needed in this and in other Examples may for example be prepared from the known (S)-2-methoxy-butyric acid [Tetrahedron 2 5 (1969) 2322] analogously to Example 39. b) Reaction to the title compound Starting from 3.47 g (0.015 mol) of (±)-21-hydroxy5, 9,9-trimethyl-6,7-benzomorphan and 2.46 g (0.018 mol) of (S)-2-methoxybutyric acid chloride, the title compound is obtained analogously to Example 1 in a yield of 1.6 g (60.3% of theory) with a melting point of 246°C (decomp.) and a specific rotation of [a]25 = +119.2° (c = 1, CH3OH). - 47 4.1.42 Example 42 ( +) - (IS, 5R, 2 S) -2 1-hydroxy-2- (2-methoxybutyl) 5,9,9-trimethyl-6,7-benzomorphan hydrochloride The mother liquor obtained in Example 41 is evaporated down. From the residue, the title compound is obtained analogously to Example 2 in a yield of 0.6 g (22.6% of theory) with a melting point of 228 °C (decomp.) and a specific rotation of [α]θ5 = -71.7° (c = 1, CH3OH) . 4.1.43 Example 43 (-) - (IR,5S,2R)-2-(2-benzyloxypropyl)-2 'hydroxy-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The (R)-2-benzyloxypropionic acid chloride used here and in other Examples may for example be prepared as follows: Commercial isobutyl (R)-(+)-lactate is O-benzylated with benzylbromide in the presence of silver oxide. The subsequent saponification with sodium hydroxide solution yields (R)-2-benzyloxy-propionic acid with a specific rotation of [ a ] J5 = +79.5° (c = 1, CH3OH) . The corresponding acid chloride is obtained from this analogously to Example 39. b) Reaction to the title compound Starting from 3.47 g (0.015 mol) of (+)-2'-hydroxy5, 9 , 9-trimethyl-6 , 7-benzomorphan and 3.3 g (0.0165 mol) of (R)-2-benzyloxypropionic acid chloride, a mixture of the expected diastereomers is obtained analogously to Example 1, which are separated by crystallisation of the corresponding hydrochlorides as described in that Example. The title compound is obtained in a yield of - 48 2.39 g (76.6% of theory) with a melting point of 250°C (decomp.) and a specific rotation of [a]p5 = -119.3° (C = 1, CH3OH) . 4.1.44 Example 44 ( + ) -(IS,5R,2S)-2-(2-benzyloxypropyl)-2’hydroxy-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The (S)-2-benzyloxypropionic acid chloride used here and in other Examples may for example be prepared analogously to Example 43 from (S)-2-benzyloxypropionic acid (specific rotation: [a]p5 = -78.5° (c = 1, CH3OH) ) . b) Reaction to the title compound Starting from 3.47 g (0.015 mol) of (+)-21-hydroxy20 5,9,9-trimethyl-6,7-benzomorphan and 3.3 g (0.0165 mol) of (S)-2-benzyloxypropionic acid chloride the title compound is obtained analogously to Example 43 in a yield of 2.56 g (82,1% of theory) with a melting point of 250°C (decomp.) and a specific rotation of [a]^5= +119.5° (c = 1, CH3OH). 4.1.45 Example 45 (-) -(IR,5S,2R)-2'-hydroxy-2-(2-methylthiopropyl) -5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The (R)-2-methylthiopropionic acid chloride required 35 here and in other Examples may for example be prepared analogously to Example 39 from the known (R)-2methylthio-propionic acid (L.N. Owen and M.B. Rahman J. - 49 Chem. Soc. [c] 1971. 2432]. b) Reaction to the title compound 1.62 g (0.007 mol) of (±)-2'-hydroxy-5,9,9-trimethyl6,7-benzomorphan are reacted analogously to Example 1 with 1.07 g (7.7 mMol) of (R)-2-methylthio-propionic acid chloride. After reduction of the reaction product with lithium aluminium hydride (LiAlH4) a mixture of the expected diastereomers is obtained, which are separated by crystallisation of their nitrates. The substance which crystallises from ethanol after acidification with 65% nitric acid and the addition of diethylether until turbidity sets in is left to stand in the refrigerator for about 12 hours, then suction filtered, washed with a mixture of ethanol and ether and then with ether and dried at 80 °C. The nitrite (0.67 g) is recrystallised from boiling ethanol (0.52 g), then converted into the free base and finally crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.43 g (34.4% of theory) with a melting point of 265°C (decomp.) and a specific rotation of [a]25 == -135.1 ° (c = 0.5 CH3OH) . 4.1.46 Example 46 ( + ) - (IS ,5R,2R)-2'-hydroxy-2-(2-methylthiopropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The mother liquor of the first nitrate crystallisation obtained according to Example 45 is evaporated down and the nitrate residue is converted into the free base.
This (1 g) is filtered over 20 g of aluminium oxide as in Example 55 and then crystallised as the hydrochloride (ethanol/ether). This hydrochloride (0.29 g) is recrystallised from a mixture of 2 ml of methanol and diethylether. The title compound is obtained in a yield - 50 of 0.21 g (16.8% of theory) with a melting point of 238 °C (decomp.) and a specific rotation of [a]25 = +73.0° (c = 0.5, CH30H) . 4.1.47 Example 47 (-) -(IR,5S,2S)-2'-hydroxy-2-(2-methylthiopropyl-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The (S)-2-methylthiopropionic acid chloride needed here and in other Examples may be prepared for example from the known (S)-2-methylthiopropionic acid [J. Chem. Soc. 1971. 2437] analogously to Example 39. b) Reaction to the title compound Starting from 1.62 g (0.007 mol) of (±)-2'-hydroxy20 5,9,9-trimethyl-6,7-benzomorphan, the title compound is obtained analogously to Example 45 in a yield of 0.42 g (33.6% of theory) with a melting point of 265°C (decomp.) and a specific rotation of [a]25 = +135.1 ° (c = 0.5, CHjOH). 4.1.48 Example 48 (-) -(IR,5S,2S)—21-hydroxy-2-(2-methylthiopropyl-5 , 9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from the nitrate mother liquor in Example 47, the title compound is obtained analogously to Example 46 in a yield of 0.34 g (27.2% of theory) with a melting point of 238°C (decomp.) and a specific rotation of [a]g5= -73.9° (c = 0.5, CHjOH). - 51 4.1.49 Example 49 ( + ) -(IS,5R,2S)-2-(2-allyloxypropyl)-2 ' hydroxy-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The (S)- (-)-2-allyloxy-propionic acid chloride used here may be prepared as follows, for example: commercial ethyl (S) - (-)-lactate is o-allylated with allylbromide in the presence of silver oxide. Subsequent saponification with sodium hydroxide solution yields (S)-2-allyloxy-propionic acid with a boiling point of 110 to 112 °C at a pressure of 15 mbar and a specific rotation of [a]*5= 78.4° (c = 1, CH3OH) . The corresponding acid chloride is obtained therefrom analogously to Example 39. b) Reaction to the title compound Starting from 3.47 g (0.015 mol) of (±)-2'-hydroxy5, 9 , 9-trimethyl-6 , 7-benzomorphan and 3.3 g (0.0165 mol) of (S)-2-allyloxy-propionic acid chloride, a mixture of the two expected diastereomers is obtained analogously to Example 1, which is separated as described therein by crystallisation of the corresponding hydrochlorides.
The title compound is obtained in a yield of 1.4 g (51.0% of theory) with a melting point of 245°C (decomp.) and a specific rotation of [a]p5 = +120° (c = 1, 0 CHjOH) . 4.1.50 Example 50 (-) -(IS,5R,2"S)-2-(2-allyloxypropyl)-2'hydroxy-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The mother liquors obtained in Example 49 are evaporated - 52 down. From the residue, the title compound is obtained analogously to Example 2 in a yield of 0.62 g (22.6% of theory) with a melting point of 213 °C and a specific rotation of [a]25 = -38.6° (c = 1, CH3OH) . 4.1.51 Example 51 (-) - (IR,5S,2R)-2'-hydroxy-2-(2-phenoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride 2.31 g (0.010 mol) of (±)-2'-hydroxy-5,9,9-trimethyl6,7-benzomorphan and 2.03 g (0.011 mol) of (R)-2phenoxypropionic acid chloride (prepared - analogously to Example 39 - from the known acid [CA 72., 12917d]) are reacted analogously to Example 1. A mixture of the two expected diastereomers is obtained which, as described therein, is separated by crystallisation of the corresponding hydrochlorides. In this way, the title compound is obtained in a yield of 1.6 g (79.6% of theory) with a melting point of 279°C (decomp.) and a specific rotation of [a]25 = -142.9° (c = 1, CH3OH) . 4.1.52 Example 52 ( + ) -(IS,5R,2S)-2'-hydroxy-2-(225 phenoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride By proceeding as in Example 1 with (S)-2-phenoxypropionic acid chloride the title compound is obtained in a yield of 1.6 g with a specific rotation of [a]25 = + 143.3°C (c = CH3OH) . - 53 4.1.53 Example 53 (-) -(IR,5S,2R)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9,21-tetramethyl-6,7-benzomorphan hydrochloride a) Starting compound The (+/-)-3'-hydroxy-5,9,9,21-tetramethyl-6,7benzomorphan required here and in other Examples is not known from the prior art. It may be prepared, for example, using the method of synthesis given for the known 2 ' -hydroxy derivative [DOS 20 27 077; CA 74 (1971), 125482X] using 3-methoxy-4-methylbenzyllithium instead of p-methoxybenzyllithium. The 3'-hydroxy15 5,9,9,2'-tetramethyl-6,7-benzomorphan which is predominantly obtained on cyclisation to the benzomorphan system is purified by flash column chromatography (cf. Example 16). b) Reaction to the title compound Starting from 2.44 g (0.010 mol) of (+/-)-3'-hydroxy5, 9 , 9 , 2 ' -tetramethyl-6 , 7-benzomorphan and 1.6 g (0.013 mol) of (R)-2-methoxypropionic acid chloride a mixture of the expected diastereomeric bases is obtained analogously to Example 1 which are separated by column chromatography on 100 times the quantity of silica gel, analogously to Example 2. The slower running substance (Rf = 0.25) is crystallised out as the hydrochloride.
The title compound is obtained in a yield of 1.06 g (59.9%) with a melting point of 181-182°C and a specific rotation of [ a ] = -89.5 (c = 1, CH3OH) . - 54 4.1.54 Example 54 ( + ) - (IS, 5R, 2 R) -3'-hydroxy-2-(2-methoxypropyl) -5,9,9,21-tetramethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf = 0.34) separated off in Example 53 is precipitated as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 1.24 g (70.1%) as an amorphous powder with a specific rotation of [a]25 = +55.9° (c = 1, CH3OH) . 4.1.55 Example 55 ( + ) - (IS , 5R,2S)-3'-hydroxy-2-(2-methoxy15 propyl)-5,9,9,21-tetramethyl-6,7-benzomorphan hydrochloride Starting from 2.44 g (0.010 mol) of (+/-)-3'-hydroxy5, 9 , 9 , 2 ' -tetramethyl-6 , 7-benzomorphan (see Example 53) and 1.6 g (0.013 mol) of (S)-2-methoxy-propionic acid chloride a mixture of the expected diastereomeric bases is obtained analogously to Example 1 which are separated by column chromatography on 100 times the quantity of silica gel analogously to Example 2. The slower running substance (Rf = 0.25) is crystallised out in the form of the hydrochloride. The title compound is obtained in a yield of 1.48 g (83.6%) with a melting point of 186-188°C and a specific rotation of [a]25 = +88.2 ° (c = 1, CHjOH). 4.1.56 Example 56 (-)-(IR,5S,2S)-3'-hydroxy-2-(2methoxypropyl)-5,9,9,2'-tetramethyl-6,7benzomorphan hydrochloride The faster running substance (Rf = 0.34) separated off in Example 55 is precipitated as the hydrochloride - 55 analogously to Example 2. The title compound is obtained in a yield of 1.40 g (79.1%) as an amorphous powder with a specific rotation of [a]p5= -56.8° (c = 1, CH3OH) . 4.1.57 Example 57 () -(IR,5S,2R)—2'-hydroxy-2-(2-methoxypropyl)5,9,9,31-tetramethyl-6,7-benzomorphan methanesulphonate a) Starting compound The (+/-)-2'-hydroxy-5,9,9,3'-tetramethyl-6,7benzomorphan required here and in other Examples is not known from the prior art. It may, for example, be prepared by the method of synthesis given for the known 2'-hydroxy derivative [DOS 20 27 077; CA 74 (1971), 125482x], using 4-methoxy-3-methylbenzyllithium instead of p-methoxybenzyl1ithium. The 2'-hydroxy-5,9,9,3 '20 tetramethyl-6,7-benzomorphan which is predominantly obtained on cyclisation to form the benzomorphan system is purified by flash column chromatography (cf. Example 16) . b) Reaction to obtain the title compound Starting from 2.44 g (0.010 mol) of (+/-)-2'-hydroxy5, 9 , 9 , 3 ' -tetramethyl-6 , 7-benzomorphan and 1.6 g (0.013 mol) of (R)-2-methoxypropionic acid chloride a mixture of the expected diastereomeric bases is obtained analogously to Example 1, which is separated by column chromatography on 100 times the quantity of silica gel analogously to Example 2. The slower running substance (Rf = 0.26) is crystallised out as the methanesulphonate.
The title compound is obtained in a yield of 1.64 g (79.3%) with a melting point of 266-268°C and a specific rotation of [a]^5 = -95.4° (c=l, CHjOH) . - 56 4.1.58 Example 58 ( + ) -(IS,5R,2R)—21-hydroxy-2-(2-methoxypropyl)-5,9,9,31-tetramethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf = 0.29) separated off in Example 57 is precipitated as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 1.60 g (90.4%) as an amorphous powder with a specific rotation of [a]25 = +73.4 ° (c = 1, CHjOH) . 4.1.59 Example 59 ( + ) - (IS,5R,2S)-21-hydroxy-2-(2-methoxy15 propyl)-5,9,9,31-tetramethyl-6,7-benzomorphan methanesulphonate Starting from 2.44 g (0.010 mol) of (+/-)-2’-hydroxy5, 9 , 9 , 3 ' -tetramethyl-6 , 7-benzomorphan (see Example 57) and 1.6 g (0.013 mol) of (S)-2-methoxy-propionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1, which is separated by column chromatography on 100 times the amount of silica gel analogously to Example 2. The slower running substance (Rf = 0.26) is crystallised out as the methanesulphonate. The title compound is obtained in a yield of 1.56 g (88.1%) with a melting point of 265-267°C and a specific rotation of [a]25 = +96.9° (c = 1, CHjOH). 4.1.60 Example 60 (-) -(IR,5S,2S)-21-hydroxy-2-(2-methoxypropyl )-5,9,9,3'-tetramethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf = 0.29) separated in Example 59 is precipitated as the hydrochloride - 57 analogously to Example 2. The title compound is obtained in a yield of 1.36 g (76.8%) as an amorphous powder with a specific rotation of [a]25 = -74.9° (c = 1, CH3OH) . 4.1.61 Example 61 (-)- (IR,5S,2R)-21,31-dihydroxy-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Starting compound The (+/-)-2',31-dihydroxy-5,9,9-trimethyl-6,7benzomorphan required here and in other Examples is not known from the prior art. It may, for example, be prepared by the method of synthesis given for the known 2'-hydroxy derivative [DOS 20 27 077; CA 74 (1971), 125482x], using 3,4-dimethoxybenzyl1ithium instead of pmethoxybenzyllithium. The 2',31-dihydroxy-5,9,920 trimethyl-6,7-benzomorphan predominantly obtained on cyclisation to form the benzomorphan system is purified by flash column chromatography (cf. Example 16). b) Reaction to form the title compound Starting from 8.51 g (0.03 mol) of (+/-)-2',3'dihydroxy-5,9,9-trimethyl-6,7-benzomorphan hydrochloride and 4.1 g (0.033 mol) of (R)-2-methoxy-propionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1, which is separated analogously to Example 2 by column chromatography on 100 times the amount of silica gel. The slower running substance (Rf = 0.21) is crystallised out as the hydrochloride.
The title compound is obtained in a yield of 2.54 g (47.6%) with a melting point of 167° (decomp.) and a - 58 specific rotation of [a]25= -98.6° (c = 0.5; CHjOH) . 4.1.62 Example 62 ( + ) - (IS ,5R,2R)-2' ,3'-dihydroxy-2-(2-methoxy5 propyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf = 0.29) separated off in Example 61 is precipitated as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 2.28 g (42.7%) with a melting point of 25l°C (decomp.) and with a specific rotation of [a]25 = +64.3 ° (c = 0.5; CH3OH) . 4.2 Compounds of type fl) - prepared according to process 1.2 4.2.1 Example 63 (±)-2'-hydroxy-2-(2-methoxyethyl)-5,9,920 trimethyl-6,7-benzomorphan hydrobromide 0.6 g (0.003 mol) of (±)-2'-hydroxy-5,9,9-trimethyl-6,7benzomorphan, 0.72 g (0.0075 mol) of 2-methoxyethylchloride, 0.11 g (0.0075 mol) of sodium iodide and 0.95 g (0.0113 mol) of sodium hydrogen carbonate are stirred in 10 ml of absolute dimethylformamide at 95 °C for 23 hours. The reaction mixture is evaporated down in a rotary evaporator, finally at 95°C under a total water jet vacuum. The residue is shaken with 25 ml of water and 25 ml of dichloromethane and the aqueous phase separated off is extracted once more with 10 ml of dichloromethane. The combined extracts are washed with water, dried with sodium sulphate and, after filtration of the drying agent, as described above, evaporated down in vacuo. The evaporation residue consisting of the free base of the title compound is crystallised as the hydrobromide analogously to Example 38. The title - 59 compound is obtained in a yield of 0.48 g (43.5% of theory) with a melting point of 247°C (decomp.). 4.2.2 Example 64 (-) -(IR,5S,2R)-2 '-hydroxy-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the alkylating agent By reduction of the ( + ) -(R)-2-methoxy-propionic acid known from the prior art with lithium aluminium hydride (LiAlH4) the (-) -(R)-2-methoxy-propanol is obtained with a boiling point of 70°C under a pressure of 76 mbar and a specific rotation of [α]^5= -15.8° (c = 100). The corresponding ( + ) -(S)-2-methoxy-propanol with a boiling point of 70 °C under a pressure of 76 mbar and a rotation of [a]p5= +16.5° (c = 100) is obtained analogously from the equally well known (-) -(S)-2-methoxy-propionic acid.
By reacting (-)-(R)-2-methoxypropanol with ptoluenesulphonic acid chloride in pyridine analogously to R.S. Tipson [J. Org. Chem. 9 (1944) 235] the ( + )-(R)2-methoxypropyl-p-toluenesulphonate is obtained in the form of a yellowish oil with a specific rotation of [a]p5= +3.7° (c = 100) and analogously, from ( + ) - (S) -2methoxy-propanol, the corresponding (-)-(S)-2methoxypropyl-p-toluenesulphonate is obtained with a rotation of [a]p5= -3.7° (c = 100). b) Reaction to form the title compound 1.16 g (5 mMol) of (±)-2'-hydroxy-5,9,9-trimethyl-6,7benzomorphan (Example 1) are heated to reflux temperature with 1.83 g (7.5 mMol) of (R)-2-methoxypropyl-p-toluenesulphonate, 1.26 g (0.015 mol) of sodium hydrogen carbonate and 1.12 g (7.5 mMol) of sodium - 60 iodide in a mixture of 15 ml of absolute dimethylformamide and 25 ml of absolute tetrahydrofuran for 60 hours with stirring. Then the mixture is worked up analogously to Example 63. A mixture of the two expected diastereomeric bases (2 g) is obtained which can also be prepared by other methods according to Example 1. The mixture is separated by crystallisation of the hydrochlorides as described in Example 1 and the title compound is obtained in a yield of 0.55 g (64.7% of theory) with a melting point of 264 °C (decomp.) and a specific rotation of [a]25 = -118.2° (c = 1, CH3OH) . The ( + ) - (IS,5R,2R)-diastereomer can be obtained from the mother liquor analogously to Example 2. 4.2.3 Example 65 (-) - (IR,5S,2R)-2-(2-methoxypropyl)-2’-nitro5,9,9-trimethyl-6,7-benzomorphan hydrochloride 2.97 g (0.010 mol) of (+)-2*-nitro-5,9,9-trimethyl-6,720 benzomorphan hydrochloride (Example 34) are reacted analogously to Example 64 with 2.68 g (0.011 mol) of (R)-2-methoxypropyl-p-toluenesulphonate, 1.65 g (0.011 mol) of sodium iodide and 2.1 g (0.025 mol) of sodium hydrogen carbonate. The reaction product which is isolated as described consists initially of a mixture of the two expected diastereomeric bases (3.2 g). In order to separate off any by-products this mixture is dissolved in 64 ml of dichloromethane and the solution is filtered through a column containing 64 g of aluminium oxide (activity stage III - neutral according to Brockmann). After eluting with a further 128 ml of dichloromethane, the combined eluates are evaporated down in a rotary evaporator, finally at 80°C under a total water jet vacuum. The residue (2.4 g) is dissolved in 10 ml of methanol and after acidification with 2.5 N ethanolic hydrochloric acid the solution is mixed with diethylether until it is just beginning to be - 61 cloudy. The title compound is crystallised and after standing for 3 days at ambient temperature it is suction filtered, washed with ethanol/ether mixture (1:1), then with ether and dried at 80‘C. The title compound is obtained in a yield of 0.84 g (45.5% of theory) with a melting point of 226°C (decomp.) and a specific rotation of [a]25 = -120° (c = 1, CH3OH) . The stereoisomeric ( + )(1S,5R,2R) compound may be obtained from the mother liquor if desired. 4.2.4 Example 66 ( + ) - (IS,5R,2S)-2-(2-methoxypropyl)-2'-nitro5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 2.97 g (0.010 mol) of (±)-2'-nitro-5,9,9trimethyl-6,7-benzomorphan hydrochloride and 2.68 g (0.011 mol) of (S)-2-methoxypropyl-p-toluenesulphonate, the title compound is obtained analogously to Example 65 in a yield of 0.96 g (52.0% of theory) with a melting point of 226 °C (decomp.) and a specific rotation of [a]25= +121° (c = CHjOH) . The stereoisomeric (-)(1R,5S,2S) form can be obtained from the mother liquor analogously to Example 2. 4.2.5 Example 67 (-)-(IR,5S,2R)-2-(2-methoxypropyl)-3'-nitro5,9,9-trimethyl-6,7-benzomorphan a) Preparation of the starting compound (±)-3'-nitro-5,9,9-trimethyl-6,7-benzomorphan required here and in other Examples is formed in addition to the (±)—2'-nitro-isomer when 5,9,9-trimethyl-6,7benzomorphan (Example 34) is nitrogenated in a ratio of about 1:3. It is obtained from the mother liquor of the 21-nitro-isomer, which is crystallised as the hydrochloride, via the base which is prepared initially. - 62 This is crystallised as the oxalate (melting point 158 °C (decomp.)) from ten times the amount of methanol. The oxalate is converted back into the base (not crystallised) which is used for the reaction described 5 below. A sample of the base, crystallised as the methanesulphonate, melts at 242°C (decomp.). b) Reaction to form the title compound .2 g (0.02 mol) of (±)-31-nitro-5,9,9-trimethyl-6,7benzomorphan are reacted analogously to Example 65 with 5.36 g (0.022 mol) of (R)-2-methoxypropyl-ptoluenesulphonate. The reaction product obtained is a mixture of the two expected stereoisomeric bases (8 g) which is purified by filtering over aluminium oxide as described in Example 65 (4.7 g of purified base mixture). In thin layer chromatography (silica gel 60, toluene/ethyl acetate 85:15, developed 3 times) the diastereomers have Rf-values of 0.81 and 0.85.
Separation of 1 g of diastereomer mixture on 300 g of silica gel by column chromatography yields the title compound (100 mg) with an Rf-value of 0.81 as a brownish, very viscous oil which does not crystallise. 4.2.6 Example 68 ( + ) -(IS,5R,2R)-2-(2-methoxypropyl)-31-nitro5,9,9-trimethyl-6,7-benzomorphan During the column chromatography of the diastereomer mixture described in Example 67, in addition to the (-)(IR,5S,2R)-form isolated there (Rf = 0.81), 100 mg of the ( + ) - (IS, 5R, 2S)-form (Rf = 0.85) are also obtained as a brownish, highly viscous oil which does not crystallise. - 63 4.2.7 Example 69 (-) -(IR,5S,2R)-2'-chioro-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound (+)-2'-chloro-5,9,9-trimethyl-6,7-benzomorphan used here and in other Examples may be prepared from the 2'-nitro analogue (Example 34), for example, by hydrogenating the latter to form the 2'-amino compound (dihydrochloride: melting point 283 °C, (decomp.)) and converting this by Sandmeyer reaction into the desired 2'-chloro-compound (hydrobromide: melting point > 310°C (decomp.). b) Reaction to form the title compound 3.3 g (0.010 mol) of (±)-2'-chloro-5,9,9-trimethyl-6,7benzomorphan hydrobromide and 2.68 g (0.011 mol) of (R)20 2-methoxypropyl-p-toluenesulphonate are reacted analogously to Example 65 to form a mixture of the two expected diastereomeric bases and purified by filtration over aluminium oxide as described therein. The purified diastereomer mixture is separated analogously to Example 1 by crystallisation of the hydrochlorides. The title compound is obtained in a yield of 0.27 g (15.1% of theory) with a melting point of 287 °C (decomp.) and a rotation of [a]p5= -102.6° (c = 1, CH3OH) . 4.2.8 Example 70 ( + ) -(IS,5R,2R)-21-chloro-2-(2-methoxypropyl)5,9,9-trimethyl-6,7-benzomorphan hydrochloride The mother liquor of Example 69 is evaporated down and the residue is dissolved with a barely sufficient quantity of boiling methanol. After the addition of diethylether until the mixture is beginning to be cloudy - 64 and after simultaneous crystallisation the title compound is obtained. After standing for about 12 hours at ambient temperature this title compound is suction filtered, washed with ethanol/ether 1:1 and then with ether and dried at 80’C. Yield 0.56 g (31.3% of theory), melting point: 289°C, specific rotation: [a]25 = + 67.9". 4.2.9 Example 71 ( + ) -(IS,5R,2S)-2'-chloro-2-(2-methoxypropyl)5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 3.3 g (0.010 mol) of (±)-21-chloro-5,9,9trimethyl-6,7-benzomorphan and 2.68 g (0.011 mol) of (S)-2-methoxypropyl-p-toluenesulphonate the title compound is obtained analogously to Example 69 in a yield of 0.41 g (22.9% of theory) with a melting point of 288 °C (decomp.) and a specific rotation of [a]25 = +101.7° (c = 1, CH30H). 4.2.10 Example 72 (-) -(IR,5S,2S)-2'-chloro-2-(2-methoxypropyl)5,9,9-trimethyl-6,7-benzomorphan hydrochloride From the mother liquors of Example 71 the title compound is obtained analogously to Example 70 in a yield of 0.75 g (41.9% of theory) with a melting point of 288’C and a specific rotation of [a]25 = -68.6° (c = 1, CH3OH) . 4.3 Compounds of type (1) - prepared according to process 1.3 4.3.1 Example 73 (-) -(IR,5S,2S)-2'-methoxy-2-(2-methoxypropyl) -5,9,9-trimethyl-6,7-benzomorphan methanesulphonate - 65 0.68 g (2 mMol) of (-) - (IR,5S,2S)-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride (Example 4) are placed in 20 ml of absolute dimethylformamide and, whilst cooling with ice and stirring, 0.13 g of 77% sodium hydride suspension in paraffin (4.2 mMol) are added thereto. After 30 minutes stirring, 0.31 g (2.2 mMol) of methyliodide, dissolved in 5 ml of dimethylformamide, are added dropwise within 5 minutes. The mixture is then stirred for a further 3 hours at ambient temperature and evaporated down in the rotary evaporator, finally at 95 °C under a total water jet vacuum. The residue is shaken with 25 ml of dichloromethane and 25 ml of water. The aqueous phase separated off is extracted once more with 15 ml of dichloromethane. After washing with 15 ml of water the combined extracts are evaporated down and the residue is crystallised as the methanesulphonate analogously to Example 28. The title compound is obtained in a yield of 0.38 g (46.0%) with a melting point of 150-152°C (decomp.) and a specific rotation of [a]25 = -68.7° (c = 1, CH3OH). 4.3.2 Example 74 (+)-(IS,5R,2R)-2'-methoxy-2-(2-methoxy25 propyl)-5,9,9-trimethyl-6,7-benzomorphan methanesulphonate Starting from 0.68 g (2 mMol) of (+)-(IS,5R,2R)-2'hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,730 benzomorphan hydrochloride (Example 2), the title compound is obtained analogously to Example 73 in a yield of 0.38 g (46.0% of theory) with a melting point of 150-152 °C (decomp.) and a specific rotation of [a]25 = + 67.2° (c = 1, CHjOH) . -66 4.3.3 Example 75 (-) -(IR,5S,2R)—2'-ethoxy-2-(2-methoxypropyl) 5,9,9-trimethyl-6,7-benzomorphan methanesulphonate Starting from 0.34 g (1 mMol) of (-)-(IR,5S,2R)-2'hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 1) and 0.17 g (0.0011 mol) of ethyliodide the title compound is obtained analogously to Example 73 in a yield of 0.30 g (70.2% of theory) with a melting point of 146-148°C (decomp.) and a specific rotation of [a]p5= -93.4° (C = 1, CH3OH) . 4.3.4 Example 76 (-) - (IR,5S,2R)-2'-acetoxy-2-(2-methoxypropyl) -5,9,9-trimethyl-6,7-benzomorphan methanesulphonate 0.68 g (2 mMol) of (-)-(IR,5S,2R)-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride (Example 1) are dissolved in 15 ml of absolute dichloromethane. After the addition of 0.51 g (5 mMol) of triethylamine the solution is mixed with 0.19 g (2.4 mMol) of acetylchloride dissolved in 5 ml of dichloromethane, with stirring, at ambient temperature, over a period of 10 minutes. Then the resulting mixture is stirred for a further 2 hours at ambient temperature. It is then washed three times with 10 ml of ice water, dried with sodium sulphate and, after the drying agent has been filtered off, the residue is evaporated down (rotary evaporator, finally at a temperature of 80°C under a total water jet vacuum).
The residue, which consists of the free base of the title compound (0.6 g, 1.74 mMol), is dissolved in 3 ml of ethanol and acidified to just pH 4 by the addition of - 67 methanesulphonic acid (0.16 g, (1.74 mMol) in 3 ml of ethanol). After the addition of diethylether until the mixture is just turning cloudy the title compound crystallises and, after being left to stand for about 12 hours in the refrigerator, it is suction filtered, washed with ethanol/ether 1:2 and dried at 80 °C. Yield 0.7 g (79.3% of theory), melting point: 183-184°C (decomp.), [a]25 = -83.9° (c = 1, CHjOH). 4.3.5 Example 77 ( + ) -(IS,5R,2S)-2’-acetoxy-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan methanesulphonate Starting from 0.68 g (0.002 mol) of ( + ) - (IS,5R,2S)-21hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 3) the title compound is obtained analogously to Example 76 in a yield of 0.6 g (68.0% of theory) with a melting point of 183-184 °C (decomp.) and a specific rotation of [a]25 = +82.8° (c = 1, CHjOH) . 4.3.6 Example 78 (-) - (IR,5S,2S)—2'-acetoxy-2-(2-methoxy2 5 propyl)-5,9,9-trimethyl-6,7-benzomorphan methanesulphonate Starting from 0.68 g (0.002 mol) of (-) - (IR,5S,2"S)-2 ' hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,730 benzomorphan hydrochloride (Example 4) the title compound is obtained analogously to Example 76 in a yield of 0.58 g (65.7% of theory) with a melting point of 183 °C (decomp.) and a specific rotation of [a]25 = -57.1° (c = 1, CHjOH). - 68 4.3.7 Example 79 ( + ) -(IS ,5R,2R)-2'-acetoxy-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan methanesulphonate Starting from 0.68 g (2 mMol) of ( +) - (IS,5R,2R)-2'hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 2) the title compound is obtained analogously to Example 76 in a yield of 0.67 g (75.9% of theory) with a melting point of 183°C and a specific rotation [ a ]25 = +58.2 ° (c = 1, CH3OH) . 4.3.8 Example 80 (-) - (IR, 5S,2R) -2-(2-methoxypropyl)-2'propionoxy-5,9,9-trimethyl-6,7-benzomorphan methanesulphonate Starting from 0.34 g (1 mMol) of (-) - (IR,5S,2R)-2'2 0 hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 1) and 0.15 g (1.1 mMol) of propionic acid anhydride, the title compound is obtained analogously to Example 76 in a yield of 0.21 g (46.1% of theory) with a melting point of 145°C (decomp.) and a specific rotation of [a]25 = -78.3 ° (c = 1, CH3OH) . 4.3.9 Example 81 (-) -(IR,5S,2R)-2-(2-methoxypropyl)-5,9,930 trimethyl-6,7-benzomorphan hydrochloride a) (-) -(IR,5S,2R)-2-(2-methoxypropyl)-2'-(1phenyl-5-tetrazolyloxy)-5,9,9-trimethyl-6,7benzomorphan hydrochloride 1.36 g (4 mMol) of (-)-(IR,5S,2R)-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan - 69 hydrochloride (Example 1) are refluxed with 0.79 g (4.4 mMol) of 5-chloro-l-phenyltetrazole and 1.36 g (0.01 mol) of dry, finely powdered potassium carbonate in 78 ml of absolute acetone for 6 days with stirring.
Then the solution is evaporated down and the residue is mixed with 50 ml of water. It is extracted twice with 25 ml of dichloromethane and the combined extracts are washed with 15 ml of water. After drying with sodium sulphate and filtering off the drying agent the reaction mixture is evaporated in a rotary evaporator, finally at 80°C under a total water jet vacuum. The residue is dissolved with 5 ml of ethanol and, after acidifying with ethanolic hydrochloric acid, mixed with diethylether until just turning cloudy. The intermediate product crystallises out and, after standing for about 12 hours in the refrigerator, is suction filtered, washed with an ethanol/ether mixture (1:1), then with ether and dried at 80°C. Yield 1.67 g (86.3% of theory), melting point 241°C (decomp.). b) Hydrogenation of the intermediate product to obtain the title compound The intermediate product (1.67 g, 3.5 mMol) is hydrogenated in the presence of 0.7 g of 10% palladium/charcoal in 70 ml of glacial acetic acid under a hydrogen pressure of 5 bar and at ambient temperature until fully reacted (6-10 hours). Then the catalyst is removed by suction filtering, the filtrate is evaporated down and the residue, after being mixed with 50 ml of water and excess ammonia, is extracted with dichloromethane (twice with 25 ml). The combined extracts are washed with water, dried with sodium sulphate and evaporated down after the drying agent has been filtered off in a rotary evaporator, finally at 80°C under a full water jet vacuum. The residue is crystallised as the hydrochloride analogously to Example - 70 2. The title compound is obtained in a total yield of 0.5 g (38.5% of theory) with a melting point of 225°C (decomp.) and a specific rotation of [a]jp = -101.5° (c = 1, CH3OH). 4.3.10 Example 82 ( + ) - (IS,5R,2S)-2-(2-methoxypropyl)-5,9,9trimethyl-6,7-benzomorphan hydrochloride Starting from 1.36 g (0.004 mol) of ( + )-(IS,5R,2S)-2'hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 3) the title compound is obtained, analogously to Example 1 by means of the corresponding intermediate product (1.65 g, 85.1% of theory, melting point 241° (decomp.)), in a total yield of 0.64 g (49.4% of theory) with a melting point of 225°C (decomp.) and a specific rotation of [a]p5 = + 106.9° (C = 1, CH-jOH) . 4.3.11 Example 83 (-) -(IR,5S,2S)-2-(2-methoxypropyl)-5,9,9trimethyl-6,7-benzomorphan oxalate Starting from 1.36 g (4 mMol) of (-) - (IR,5S,2S)-2125 hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 4) the title compound is obtained in the form of the free base (0.7 g) via the corresponding intermediate product (1.73 g, 89.4% of theory, melting point 218.5°C (decomp.). This base is dissolved with 2 ml of isopropanol and mixed with the corresponding molecular quantity of oxalic acid (0.22 g) . The title compound is crystallised while 50 ml of diethylether are gradually added with stirring. After being kept for about 12 hours in the refrigerator the mixture is suction filtered, washed with isopropanol/ether, then with ether and dried at 80°C. The title compound is obtained in a - 71 yield of 0.8 g (53.0% of theory) with a melting point of 135’C (decomp.) and a specific rotation of [a]25 = -60.0° (C = 1, CH3OH). 4.3.12 Example 84 ( + ) - (IS, 5R,2R)-2-(2-methoxypropyl)-5,9,9trimethyl-6,7-benzomorphan oxalate Starting from 1.36 g (4 mMol) of ( + )-(IS ,5R,2R)-2110 hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 2) the base of the title compound is obtained analogously to Example 1 via the corresponding intermediate product (1.65 g, 85.1% of theory, melting point 217 °C (decomp.)), and is crystallised out as the oxalate analogously to Example 83. Total yield 0.6 g (39.7% of theory), melting point: 135°C (decomp.), specific rotation: [a]25 = + 60.2° (c = 1, CH3OH) . 4.3.13 Example 85 (-) - (IR,5S,2R)-21-acetamido-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan hydrochloride 0.70 g (1.87 mmol) of (-) - (IR,5S,2R)-2'-amino-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan dihydrochloride (Example 34) are dissolved in 20 ml of absolute dichloromethane, mixed with 0.76 g (7.4 mMol) of triethylamine and then, with stirring, at ambient temperature, 0.17 g (2.1 mMol) of acetylchloride dissolved in 5 ml of dichloromethane are added dropwise thereto. The mixture is then refluxed for 1 hour, cooled, washed three times with 10 ml of water, dried with sodium sulphate and, after the drying agent has been filtered off in a rotary evaporator, finally at 80°C under a full water jet vacuum, concentrated by evaporation. The residue is dissolved in 2 ml of - 72 methanol and after acidification with 2.5 N ethanolic hydrochloric acid the solution is mixed with diethylether until just beginning to go cloudy. The crystals precipitated are suction filtered (after standing for about 12 hours in the refrigerator), washed with an ethanol/ether mixture (1:1), then with ether and dried at 80°C. The title compound is obtained in a yield of 0.49 g (68.8% of theory) with a melting point of 252 °C (decomp.) and a specific rotation of [a]25 = -108.2° (c = 1, CH3OH) . 4.3.14 Example 86 ( + ) -(IS,5R,2S)-2 '-acetamido-2-(2-methoxypropyl) -5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 1.07 g (2.58 mMol) of ( + )-(IS,5R,2S)-2amino-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 36) the title compound is obtained analogously to Example 85 in a yield of 0.73 g (74.3% of theory) with a melting point of 249 °C (decomp.) and a specific rotation of [a]25 = + 109.5° (c = 1, CH3OH) . 4.3.15 Example 87 (-) - (IR,5S,2S)-21-acetamido-2-(2-methoxypropyl) -5,9,9-trimethyl-6,7-benzomorphan 1.09 g (0.0026 mol) of (-)-(IR,5S,2S)-2'-amino-2-(230 methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan dihydrochloride are reacted analogously to Example 85. The reaction product is isolated as described therein and crystallised from 0.5 ml of isopropanol and 5 ml of petroleum ether. The title compound is obtained in a yield of 0.7 g (76.4% of theory) with a melting point of 128 °C and a specific rotation of [a]25 = -89.3 ° (c = 1, CH3OH -IN HCl 1:1). - 73 4.3.16 Example 88 ( + ) - (IS,5R,2"R)-2'-acetamido-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan Starting from 1.11 g (2.5 mMol) of ( + ) - (IS,5R,2R)-2'amino-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan dimethanesulphonate (Example 35), the title compound is obtained analogously to Example 87 in a yield of 0.37 g (47.7% of theory) with a melting point of 129°C and a specific rotation of [α]θ5= +89.9° (c = 1, CH3OH -IN HCl 1: 1) . 4.3.17 Example 89 (-)-(IR,5S,2R)-31-bromo-2'-hydroxy-2-(215 methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride 0.85 g (2.5 mMol) of (-) - (IR,5S,2R)-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride (Example 1) are suspended in 30 ml of glacial acetic acid. 0.15 ml (0.47 g, 2.9 mMol) of bromine are added to the suspension with stirring at ambient temperature. After 2 hours’ stirring the mixture is evaporated down in a rotary evaporator, finally at 80°C under a total water jet vacuum. The residue is mixed with 25 ml of water and 25 ml of dichloromethane with ammonia in excess, with agitation. The aqueous phase separated off is extracted once more with 15 ml of dichloromethane, the combined extracts are washed with 15 ml of water, dried with sodium sulphate and, after the drying agent has been filtered off - as described above - concentrated by evaporation. The residue (1 g) is purified by chromatography over a column containing 250 g of silica gel analogously to Example 2, using a mixture of dichloromethane, methanol and cone, ammonia (90:10:0.5). The eluates containing the pure substance are evaporated down as above and the - 74 residue is crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.75 g (65.8% of theory) with a melting point of 245°C (decomp.) and a specific rotation of [α]^5 = -82.5° (c =1, CH3OH). 4.3.18 Example 90 ( + ) -(IR,5R,2R)-21-hydroxy-1·-nitro-2-(2methoxypropyl)-5,9,9-trimethyl-6,710 benzomorphan hydrochloride 0.85 g (2.5 mMol) of (-)-(IR,5S,2R)-21-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride are suspended in 30 ml of glacial acetic acid at 20°C and 0.18 ml (0.25 g) of 65% nitric acid (2.6 mMol of HNO3) are added with stirring. Within about 10 minutes a clear yellow solution is formed which turns brown after another 5 minutes and begins to turn cloudy as a crystalline compound is precipitated. After a reaction time of 1 hour in total the mixture is suction filtered and washed with a glacial acetic acid/diethylether mixture (1:1), then with ether and dried at 80 °C. The crystals (0.35 g) are dissolved in a hot methanol/water mixture (17.5 ml + 1.75 ml) and diethylether (40 ml) is added to the solution. After cooling in an ice bath the substance which crystallises out is suction filtered, washed with ether and dried at 80°C. The title compound is obtained in a yield of 0.32 g (33.3% of theory) with a melting point of > 245°C (with gradual brown coloration and decomposition); specific rotation [α]θ5 = +87.0° (c = 1, CH3OH) . - 75 4.3.19 Example 91 (-)-(IR,5S,2R)-2'-hydroxy-2-(2-methoxypropyl)-3'-nitro-5,9,9-trimethyl-6,7benzomorphan hydrochloride The nitrogenation described in Example 90 produces from the starting compound (Rf = 0.57) the 11-nitro-derivative described above (Rf = 0.45), the isomeric 3'-nitroderivative (Rf = 0.72) and the 1',3'-dinitro-derivative (Rf = 0.10) (TLC: silica gel 60, chloroform/methanol/conc. ammonia 90:10:0.5). The mother liquor remaining (Example 90) after the suction filtering of the 1'-nitro compound is evaporated down and the residue is converted into the free bases. These are dissolved in 10 ml of dichloromethane and the yellow solution is filtered over 25 g of aluminium oxide (activity III, neutral). The solution is eluted with dichloromethane until the eluate is no longer a strong yellow colour and the eluate is then evaporated down.
The residue (0.35 g) is dissolved in 2.5 ml of ethanol and, after acidification with ethanolic hydrochloric acid, diethylether is added to the solution until it is just beginning to turn cloudy. After it has stood for about 12 hours in the refrigerator it is suction filtered, washed with an ethanol/ether mixture (1:1) and dried at a temperature of 80°C. The title compound is obtained in a yield of 0.40 g (41.6% of theory) with a melting point of 229-230’C (decomp.) and a specific rotation of [a]25 = -110.1° (c = 1, CHjOH). 4.3.20 Example 92 (+)-(IR,5R,2R)-2',3'-dinitro-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride 1.52 g (5 mMol) of (-)-(IR,5S,2R)-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan - 76 (Example 1) are dissolved in 3 ml of glacial acetic acid and, whilst stirring at 3-4 °C, a mixture of 3.4 ml of glacial acetic acid and 5.42 ml of 100% nitric acid are added to the solution within 1.5 hours. The resulting mixture is stirred for a further 3 hours at ambient temperature. Then the yellow reaction mixture is poured into 50 g of ice water, the solution is made ammoniacal and extracted three times with 20 ml of dichloromethane. After the combined extracts have been washed with water and dried over sodium sulphate and the drying agent has been filtered off, the reaction mixture is evaporated down in a rotary evaporator, finally at 80 °C under a total water jet vacuum. The residue is crystallised from an ethanol/ether mixture. The title compound is obtained in a yield of 1.0 g (46.5% of theory) with a melting point of > 300°C (decomp.) and a specific rotation of [a]25 = +27.9 ° (c - 1, CH3OH) . 4.3.21 Example 93 (-) -(IR,5R,2R)-1'-amino-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride 0.35 g (1.0 mMol) of ( + )-(IR,5R,2R)-2'-hydroxy-2-(225 methoxypropyl)-1'-nitro-6,7-benzomorphan hydrochloride (Example 90) are hydrogenated in 40 ml of methanol in the presence of 0.1 g of palladium/charcoal (5% Pd) for 4 hours under a hydrogen pressure of 5 bar at ambient temperature. After the catalyst has been filtered off the reaction mixture is evaporated down in a rotary evaporator, finally at 80°C under a total water jet vacuum and the residue is crystallised from 10 ml of ethanol. After cooling in an ice bath the crystals are suction filtered, washed with an ethanol/ether mixture and dried at 80°C. The title compound is obtained in a yield of 0.17 g (52.7% of theory) with a melting point of 282 °C (after slow decomposition from 250 °C) and a - 77 specific rotation of [a]25 = -128.3° (c = 1, CH3OH) . 4.3.22 Example 94 (-) -(IR,5S,2R)-31-amino-2'-hydroxy-2-(25 methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride Starting from 0.39 g (1.0 mMol) of (-) - (IR,5S,2R)-2'hydroxy-2-(2-methoxypropyl)-31-nitro-5,9,9-trimethyl10 6,7-benzomorphan hydrochloride (Example 91) the title compound is obtained analogously to Example 93 in a yield of 0.27 g (76.1% of theory) with a melting point of 268 °C (decomp.) and a specific rotation of [a]25 = -99.7° (c = 0.5, CH3OH). 4.3.23 Example 95 (-) -(IR,5R,2R)-11,31-diamino-2 1-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride Starting from 0.70 g (1.63 mMol) of ( + )-(IR,5R,2R)1',3'-dinitro-21-hydroxy-2-(2-methoxy-propyl)-5,9,9trimethyl-6,7-benzomorphan hydrochloride (Example 92) the title compound is obtained analogously to Example 93 in a yield of 0.20 g (33.2% of theory) with a melting point of 228 °C (decomp.) and a specific rotation of [a]25= -111.7° (c = 0.5, CH30H) . 4.3.24 Example 96 0 (-) -(IR,5S,2R)-31-amino-2-(2-methoxypropyl)5,9,9-trimethyl-6,7-benzomorphan The diastereomixture obtained according to Example 67 consisting of (-)-(IR,5S,2R)- and ( + ) - (IS,5R,2R)-2-(235 methoxypropyl)-31-nitro-5,9,9-trimethyl-6,7-benzomorphan (3.7 g) is dissolved in 75 ml of methanol and hydrogenated in the presence of 0.8 g of - 78 palladium/charcoal (5% Pd) under a hydrogen pressure of 5 bar and a temperature of 20 °C until the uptake of hydrogen ceases (about 3 hours). In thin layer chromatography (silica gel 60, chloroform/methanol/conc. ammonia 90:10:0.5) it is found that the 3'-nitro compounds (Rf = 0.73) have reacted completely to form the corresponding 31-amino-compounds (Rf = 0.61). After the catalyst has been filtered off the reaction mixture is evaporated down in a rotary evaporator, finally at 80°C under a total water jet vacuum. The residue (3.1 g) is subjected to column chromatography on 600 g of silica gel analogously to Example 2. The separation of the diastereomeric 31-amino-compounds is monitored by thin layer chromatography (silica gel 60, chloroform/methanol/conc. ammonia 95:5:0.1, developed twice). The title compound with the smaller Rf value of 0.63 is obtained in a yield of 0.95 g as the evaporation residue of the corresponding eluates with a specific rotation of [a]p5 = -39.8° (c = 1, CH3OH) which has hitherto resisted all attempts at crystallisation. 4.3.25 Example 97 ( + ) - (IS,5R,2R)-3’-amino-2-(2-methoxypropyl)5,9,9-trimethyl-6,7-benzomorphan In the separation of the diastereomers by column chromatography described above (Example 96) the substance with the greater Rf value of 0.69 obtained is the title compound in the form of the evaporation residue of the eluates in question (1.0 g, specific rotation: [α]θ5 = +104 (c = 1, CH3OH)) , which has hitherto withstood all attempts at crystallisation. - 79 4.3.26 Example 98 ( + ) -(IS,5R,2S)-3 '-amino-2-(2-methoxypropyl)5,9,9-trimethyl-6,7-benzomorphan a) 31-nitro-precursor (mixture of diastereomers) Starting from 5.2 g (0.02 mol) of (±)-3'-nitro-5,9,9trimethyl-6,7-benzomorphan and 5.36 g (0.022 mol) of (S)-2-methoxypropyl-p-toluene-sulphonate and a mixture of the two expected diastereomeric bases is obtained analogously to Example 67 and is purified by filtration over aluminium oxide, resulting in 4.7 g of purified base mixture. b) 3'-amino-compounds (mixture of diastereomers) The 3'-nitro-precursor (4.7 g of purified mixture of diastereomers) is hydrogenated analogously to Example 96 to form the corresponding 3'-amino compounds (3.7 g of mixture of diastereomers). c) Separation of the title compound by column chromatography The mixture of diastereomeric 3'-amino-compounds (3.7 g) is separated by column chromatography on silica gel analogously to Example 96. The title compound with the smaller Rf value of 0.63 is obtained in a yield of 1.0 g as the evaporation residue of the eluates in question with a specific rotation of [a]25 * * * * 30 = +40.5° (c = 1, CHOH) , which has hitherto withstood all attempts at crystallisation. - 80 4.3.27 Example 99 (-) - (IR,5S,2S)-3 1-amino-2-(2-methoxypropyl) 5,9,9-trimethyl-6,7-benzomorphan In the column chromatography described above (Example 98) the title compound is obtained as the second substance with the greater Rf value of 0.69, in the form of the evaporation residue of the eluates in guestion in a quantity of 1.1 g, specific rotation: [ a ] &5= -105° (c = 1, CH3OH) , and has not hitherto crystallised. 4.3.28 Example 100 (-) - (IR,5S,2R)-31-acetamido-2-(2-methoxypropyl) -5,9,9-trimethyl-6,7-benzomorphan 0.95 g (3.14 mMol) of (-)-(IR,5S,2R)-3'-amino-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan (Example 96) are acetylated analogously to Example 85. The acetylation product is purified by filtration over aluminium oxide analogously to Example 65. In thin layer chromatography (silica gel 60, chloroform/methanol/conc. ammonia 90:10:0.5) the starting compound has an Rf value of 0.64 and the acetylation product has an Rf value of 0.57. The evaporation residue (0.69 g), which has hitherto resisted all attempts at crystallisation, has a specific rotation of [a]*5= -53.6° (c = 1, CH3OH) . 4.3.29 Example 101 ( + ) - (IS,5R,2R)-3 *-acetamido-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan oxalate Starting from 1.0 g (3.31 mMol) of ( + ) - (IS, 5R, 2R)-3 1 35 amino-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan (Example 97) the title compound is obtained analogously to Example 100. The evaporation residue of - 81 the substance purified over aluminium oxide (0.5 g) is crystallised in the form of the oxalate analogously to Example 83. The title compound is obtained in a yield of 0.4 g (27.8% of theory) with a melting point of 148°C (decomp.) and a specific rotation of [α]&5 = +39.3° (c = 1, CH30H) . 4.3.30 Example 102 ( + ) - (IS,5R,2S)-3’-acetamido-2-(2-methoxy10 propyl)-5,9,9-trimethyl-6,7-benzomorphan Starting from 1.0 g (3.31 mMol) of ( + ) - (IS ,5R,2S)-3'amino-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan (Example 98) the title compound is obtained analogously to Example 100 as a non-crystallising evaporation residue (0.6 g, 41.7% of theory) with an Rf value of 0.57 and a rotation of [a]p5 = +52.8° (c = 1, CH3OH) . 4.3.31 Example 103 (-) - (IR, 5S , 211S) - 3 ' -acetamido-2 - (2-methoxypropyl) -5,9,9-trimethyl-6,7-benzomorphan oxalate Starting from 0.95 g (3.14 mMol) of (-) - (IR, 5S, 2S)-3 1 amino-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan (Example 99) the title compound is obtained analogously to Example 101 in a yield of 0.7 g (51.1%) with a melting point of 148°C (decomp.) and a specific rotation of [a]^5 = -39.2° (c = 1, CH3OH) . 4.3.32 Example 104 (-)-(IR, 5S,2R)-31-methoxy-2-(2-methoxypropyl )-5,9,9,21-tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.71 g (2 mMol) of (-)-(IR,5S,2R)-3'IE 922144 - 82 hydroxy-2-(2-methoxypropyl)-5,9,9,21-tetramethyl-6,7benzomorphan hydrochloride (Example 53) the title compound is obtained analogously to Example 73 in a yield of 0.38 g (52.0%) with a melting point of 221-224°C and a specific rotation of [a]25 * * * * 30= -82.6° (c = 1, CH30H) . 4.3.33 Example 105 ( + ) -(IS,5R,2R)-3’-methoxy-2-(2-methoxy10 propyl)-5,9,9,21-tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.71 g (2 mMol) of ( + ) - (IS ,5R,2R)-3'hydroxy-2-(2-methoxypropyl)-5,9,9,2'-tetramethyl-6,715 benzomorphan hydrochloride (Example 54) the title compound is obtained analogously to Example 73 in a yield of 0.44 g (59.8%) as an amorphous powder with a specific rotation of [a]25 = +42.2 ° (c = 1, CH3OH) . 4.3.34 Example 106 ( + ) -(IS,5R,2S)-3'-methoxy-2-(2-methoxypropyl )-5,9,9,21-tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.71 g (2 mMol) of ( + )-(IS,5R,2S)-3'hydroxy-2-(2-methoxypropyl)-5,9,9,21-tetramethyl-6,7benzomorphan hydrochloride (Example 55) the title compound is obtained analogously to Example 73 in a yield of 0.40 g (54.7%) with a melting point of 221-224°C and a specific rotation of [a]25 = +81.7° (c = 1, CH3OH). - 83 4.3.35 Example 107 (-) - (IR,5S,2S)-3'-methoxy-2-(2-methoxypropyl) -5,9,9,21-tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.71 g (2 mMol) of (-)-(IR,5S,2S)-3'hydroxy-2-(2-methoxypropyl)-5,9,9,21-tetramethyl-6,7benzomorphan hydrochloride (Example 56) the title compound is obtained analogously to Example 73 in a yield of 0.42 g (56.1%) as an amorphous powder with a specific rotation of [a]25= -41.0° (c = 1, CH3OH) . 4.3.36 Example 108 (-) - (IR,5S,2R)-21-methoxy-2-(2-methoxy15 propyl)-5,9,9,31-tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.71 g (2 mMol) of (-)-(IR,5S,2R)-21hydroxy-2-(2-methoxypropyl)-5,9,9,3'-tetramethyl-6,720 benzomorphan hydrochloride (Example 57) the title compound is obtained analogously to Example 73 in a yield of 0.36 g (49.3%) with a melting point of 221-224°C and a specific rotation of [a]25= -112.2° (C = 1, CH3OH). 4.3.37 Example 109 ( + ) -(IS,5R,2R)-2'-methoxy-2-(2-methoxypropyl )-5,9,9,3'-tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.71 g (2 mMol) of ( + )-(IS,5R,2R)-21hydroxy-2-(2-methoxypropyl)-5,9,9,3'-tetramethyl-6,7benzomorphan hydrochloride (Example 58) the title compound is obtained analogously to Example 73 in a yield of 0.39 g (53.0%) as an amorphous powder with a specific rotation of [a]25 = +72.4° (c = 1, CH3OH) . - 84 4.3.38 Example 110 ( + ) - (IS,5R,2S)—2'-methoxy-2-(2-methoxypropyl) -5,9,9,31-tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.64 g (2 mMol) of ( + )-(IS,5R,2S)-2’hydroxy-2-(2-methoxypropyl)-5,9,9,3'-tetramethyl-6,7benzomorphan hydrochloride (Example 59) the title compound is obtained analogously to Example 73 in a yield of 0.45 g (61.5%) with a melting point of 228-229°C and a specific rotation of [a]p5= +111.5° (c = 1, CH3OH). 4.3.39 Example 111 (-)-(IR,5S,2S)-2'-methoxy-2-(2-methoxypropyl )-5,9,9,31-tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.71 g (2 mMol) of (-)-(IR,5S,2S)-2’20 hydroxy-2-(2-methoxypropyl)-5,9,9,3'-tetramethyl-6,7benzomorphan hydrochloride (Example 60) the title compound is obtained analogously to Example 73 in a yield of 0.40 g (53.4%) as an amorphous powder with a specific rotation of [α]^5 = -71.8° (c = 1, CH3OH) . 4.3.40 Example 112 (-) -(IR,5S,2R)-31-hydroxy-2'-methoxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrobromide Starting from 3.56 g (10 mMol) of (-)-(IR,5S,2"R)-21,3’dihydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 61) a mixture of the two isomeric monomethoxy derivatives and the dimethoxy derivative is obtained analogously to Example 73, except with two equivalents of sodium hydride, and this mixture is separated by column chromatography on 100 times the - 85 quantity of silica gel analogously to Example 2 [eluant: dichloromethane/isopropanol/conc. ammonia 97:3:03]. The compound which runs out as the middle substance (Rf = 0.73) is crystallised as the hydrobromide. The 5 title compound is obtained in a yield of 0.62 g (15.0%) with a melting point of 212°C (decomp.) and a specific rotation of [a]25= -78.4° (c = 0.5; CH3OH) . 4.3.41 Example 113 (-) -(IR,5S,2R)-2'-hydroxy-3'-methoxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrobromide The slower running substance (Rf = 0.68) separated off in Example 112 is precipitated as the hydrobromide. The title compound is obtained in a yield of 0.88 g (21.2%) with a melting point of 235°C (decomp.) and with a specific rotation of [a]25 = -93.1° (c = 0.5; CH3OH) . 4.3.42 Example 114 (-)-(IR,5S,2R)-2',3'-dimethoxy-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf = 0.86) separated off in Example 112 is precipitated as the hydrochloride. The title compound is obtained in a yield of 0.87 g (22.7%) with a melting point of 193 °C (decomp.) and a specific rotation of [ce]= -93.2° (c = 0.5; CH3OH) . - 86 4.4 Compounds of type (1) - prepared by other methods 4.4.1 Example 115 (-) -(IR,5S,2R)-21-hydroxy-2-(2-hydroxy5 propyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride 1.5 g (3.60 mMol) of (-)-(IR,5S,2R)-2-(2benzyloxypropyl)-2'-hydroxy-5,9,9-trimethyl-6,710 benzomorphan hydrochloride (Example 43) are dissolved in 75 ml of methanol and hydrogenated in the presence of palladium hydroxide on activated charcoal (0.6 g of moist Pearlman catalyst) under a hydrogen pressure of 5 bar and at a temperature of 70°C until completely reacted (about 6.2 hours). Then the catalyst is filtered off and the filtrate is evaporated down in a rotary evaporator, finally at 80°C under a total water jet vacuum. The residue is dissolved in 10 ml of methanol and 30 ml of diethylether are added to the solution. The crystals precipitated are left to stand for about 12 hours at ambient temperature, then suction filtered, first with an ethanol/ether mixture (1:1), then with ether, and dried at 80°C. The title compound is obtained in a yield of 1.0 g (85.5% of theory) with a melting point of 276° (decomp.) and a specific rotation of [ a ]25 = -127.4° (c = 1, CHjOH). 4.4.2 Example 116 ( + ) - (IS, 5R, 2 S) -2 1-hydroxy-2-(2-hydroxy30 propyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 1.5 g (3.6 mMol) of ( + )-(IS,5R,2S)-2-(2benzyloxypropyl)-2'-hydroxy-5,9,9-trimethyl-6,735 benzomorphan hydrochloride (Example 44) the title compound is obtained analogously to Example 115 in a yield of 1.0 g (85.5% of theory) with a melting point of - 87 276° (decomp.) and a specific rotation of [a]25 = +126.8 (c = 1, CH3OH) . 4.4.3 Example 117 (-) -(IR,5S,2S)-21-hydroxy-2-(2-hydroxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The diastereomer remaining in the mother liquor 10 according to Example 44 (3.17 g of evaporation residue) is hydrogenated analogously to Example 115. The title compound is obtained in a yield of 1.5 g (56.2% of theory) with a melting point of 247 °C (decomp.) and a specific rotation of [a]25- -86.8° (c = 1, CH3OH) . 4.4.4 Example 118 ( + ) - (IS,5R,2R)-2'-hydroxy-2-(2-hydroxypropyl )-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The diastereomer remaining in the mother liquor according to Example 43 (3.17 g of evaporation residue) is hydrogenated analogously to Example 115. The title compound is obtained in a yield of 1.5 g (56.2% of theory) with a melting point of 247 °C (decomp.) and a specific rotation of [aj25 = +86.4 ° (c = 1, CH3OH) . 4.4.5 Example 119 ( + ) -(1R/S,5S/R,2S)-2 *-fluoro-2-(2-methoxy30 propyl)-5,9,9-trimethyl-6,7-benzomorphan oxalate a) Starting compound: (1R/S,5S/R,2S)-2'-fluoro-2-(2methoxypropionyl)-5,9,9-trimethyl-6,7-benzomorphan (mixture of diastereomers) .94 g (0.02 mol) of (±)-2'-nitro-5,9,9-trimethyl-6,7IE 922144 - 88 benzomorphan hydrochloride are acylated analogously to Example 32 with 2.68 g (0.22 mol) of (S)—2— methoxypropionic acid chloride. The acylation product thus obtained (7.0 g) is hydrogenated as described therein to form the corresponding 21-amino-analogue.
This latter is reacted, using methods known from the prior art [T.L. Fletcher and M.J. Namkung, Chem. and Ind. 1961. 179] to form the corresponding 2'-fluoro derivative (5.7 g). This results in a mixture of the expected diastereomers, which cannot be separated by thin layer chromatography (Rf = 0.73, silica gel, chloroform/methanol/conc. ammonia 90:10:0.5). b) Reaction to obtain the title compound 1.58 g (5 mMol) of the precursor are reduced with lithium aluminium hydride (LiAlH4) to form the title compound analogously to Example 32 and purified by column chromatography on silica gel as described therein. The evaporation residue of the eluates with the purified substance (0.4 g, Rf = 0.78) is crystallised as the oxalate analogously to Example 83. The title compound is obtained in a yield of 0.35 g (17.7% of theory) with a melting point of 165 °C (decomp.) and with a rotaton of [a]25= +9.7° (c = 1, CH3OH) . The substance consists of a mixture of the expected diastereomers ((IR,5S,2S)- and (IS ,5R2"S)-compound) in a ratio of about 1:1 (determined by 1H-NMR spectroscopy). 4.4.6 Example 120 (-)-(1R/S,5S/R,2R)-2'-fluoro-2-(2-methoxypropyl )-5,9,9-trimethyl-6,7-benzomorphan oxalate a) Starting compound: (1R/S,5S/R,2R)-2'-fluoro-2-(2methoxypropionyl)-5,9,9-trimethyl-6,7-benzomorphan (mixture of diastereomers) - 89 Starting from 2.97 g (0.01 mol) of (+)-21-nitro-5, 9,9trimethyl-6,7-benzomorphan hydrochloride, a mixture of the expected diastereomeric 21-fluoro-2-(2methoxypropionyl)-5,9,9-trimethyl-6,7-benzomorphans is 5 obtained, using 1.34 g (0.011 mol) of (R)-2-methoxypropionic acid chloride (reaction sequence as in Example 119). These diastereomers cannot be separated by thin layer chromatography (Rf = 0.73, silica gel, chloroform/methanol/conc. ammonia 90:10:0.5), yield: 2.9 g. b) Reaction to form the title compound 2.9 g (9.2 mMol) of the above precursor are reduced with lithium aluminium hydride analogously to Example 119 to obtain the title compound. The reaction is purified as described therein. The evaporation residue of the pure fractions (0.9 g) is crystallised as the oxalate analogously to Example 98. The title compound is obtained in a yield of 0.88 g (22.3% of theory) with a melting point of 169 °C (decomp.) and a specific rotation of [α]θ5 = -9.5° (c = 1, CH30H) in the form of a mixture of the expected diastereomers ((IR,5S,2R)- and (IS ,5R,2R)-compounds) .
Claims (20)
1. Claims wherein X represents an oxygen or sulphur atom; R 1 represents a C^g-alkyl, C 3 . 6 -alkenyl, C 3 . 6 alkynyl or aryl group; R 2 represents a alkenyl, C 36 ~ hydrogen atom or alkynyl, aryl or a C^g-alkyl, C 3 . 6 aralkyl group; R 3 represents a group; hydrogen atom or a C^g-alkyl R 4 represents a C^g-alkyl group; R 5 represents a C^g-alkyl group; R 6 represents a C^g-alkyl or aryl group; and R 7 and R 8 , which may be identical or different, each represent a hydrogen or halogen atom or a C^g-alkyl, -OH, C^g-alkoxy, -O-acyl, -CN, -NO 2 , NH 2 , -NH (C 1 8 -alkyl) , -NH-acyl, -N-acyl(C^g-alkyl), or -N(C^g-alkyl) 2 group (wherein the alkyl groups may be identical or - 91 and all racemic, enantiomeric and diastereomeric forms thereof and mixtures thereof and acid addition salts thereof.
2. Compounds as claimed in claim 1 wherein different); X represents an oxygen or sulphur atom; 1 represents a methyl, ethyl, propyl, isopropyl or phenyl group; R 2 represents a methyl, ethyl, propyl, isopropyl, allyl, propargyl, phenyl or benzyl group; R 3 represents a hydrogen atom or a C, 4 -alkyl group; R 4 represents a methyl, ethyl, propyl or isopropyl group; R 5 represents a methyl, ethyl, propyl or isopropyl group; R 6 represents a methyl, ethyl, propyl, isopropyl or phenyl group; R 7 represents a fluorine or chlorine atom or a hydroxy, lower alkyl, lower alkoxy or acyloxy group; and R 8 represents a hydrogen atom or a lower alkyl, hydroxy or alkoxy group. Compounds as claimed in claim 1 or claim 2 wherein - 92 X represents an oxygen atom; R 1 represents a methyl or ethyl group; R 2 represents a methyl or ethyl group; R 3 represents a hydrogen atom; R 4 represents a methyl or ethyl group; R 5 represents a methyl or ethyl group; R 6 represents a methyl or ethyl group; R 7 represents a hydroxy, methyl, methoxy or acyloxy group; and R 8 represents a hydrogen atom or a methyl, ethyl hydroxy or lower alkoxy group.
3. 4. Compounds as claimed in any one of claims 1 to 3 wherein X represents an oxygen atom; R 1 represents a methyl group; R 2 represents a methyl group; R 3 represents a hydrogen atom; R 4 represents a methyl group; R 5 represents a methyl group; R 6 represents a methyl group; - 93 R 7 represents a hydroxy, methyl, methoxy or acetoxy group; and R 8 represents a hydrogen atom or a methyl,
4. 5 hydroxy, methoxy or ethoxy group. 5. Compounds as claimed in any one of claims 1 to 4 wherein the substituents R 7 and R 8 are in the 2'-position and 3'-position respectively and the 2-carbon atom has 10 the R-configuration.
5.
6. Compounds as claimed in any one of claims 1 to 5 as herein specifically described. 15
7. Compounds as claimed in any one of claims 1 to 5 as herein specifically described in any one of the Examples.
8. A process for the preparation of a compound of 20 general formula (I) as claimed in claim 1 wherein either a) a compound of general formula (2) (wherein R 4 , R 5 25 and R 6 are as defined in claim 1 and R 9 and R 10 are either as defined in claim 1 for R 7 and R 8 or represent groups which can be converted into the latter in a known manner) is reacted with a carboxylic acid derivative of general formula (4) 30 (wherein Y represents a leaving group, capable of being substituted by a secondary amino group, and R 1 , R 2 , R 3 and X are as defined in claim 1) (2) (3) - 94 and the resulting acid amide of formula (3) is subseguently reduced to obtain the amine of general formula (6) and, where necessary, the substituents R 9 and R 10 as defined above are converted into R 7 and R 8 as 15 defined in claim 1, and the compound of formula (I) thereby obtained is isolated; b) a compound of general formula (2) R 1 (wherein R 4 , R 5 , R 6 , R 9 and R 10 are as defined above in a)) is reacted with an alkylating agent of general formula (5) (wherein Z represents a leaving group, which can be substituted by a secondary amino group, and R 1 , R 2 , R 3 and X are as defined in claim 1), to obtain the tertiary amine of formula (6) and, where necessary, the substituents R 9 and R 10 as defined above are converted into R 7 and R 8 as defined in claim 1, and the compound of formula (I) thereby obtained is isolated.
9. A process as claimed in claim 8, in which in a) the leaving group Y is selected from halogen, hydroxy, 15 OC(O)alkyl, O-alkyl, OSO 2 alkyl and OSO 2 aryl.
10. A process as claimed in claim 8, in which in b) the leaving group Z is selected from halogen, OSO 2 aryl, OSO 2 alkyl, haloalkylsulphonate and sulphate.
11. A process as claimed in any one of claims 8 to 10 substantially as herein described.
12. A process as claimed in any one of claims 8 to 10 25 substantially as herein described in any one of the Examples .
13. Compounds as claimed in claim 1 whenever prepared by a process as claimed in any one of claims 8 to 12.
14. Pharmaceutical compositions comprising as active ingredient at least one compound of formula (I), as claimed in any one of claims 1 to 7 or 13, in the form of a single enantiomer or diastereoisomer or mixtures 35 thereof, or a physiologically acceptable acid addition salt thereof in association with one or more pharmaceutically acceptable carriers, diluents or excipients.
15. Compositions as claimed in claim 14 substantially as herein described.
16. Compositions as claimed in claim 15 substantially as herein described in any one of the Examples.
17. Compounds of general formula (I) as claimed in any 10 one of claims 1 to 7 or 13 and physiologically acceptable acid addition salts thereof for use in therapy.
18. The use of a compound of general formula (I) as 15 claimed in any one of claims 1 to 7 or 13 or a physiologically acceptable acid addition salt thereof for the preparation of a medicament for use in the prevention, treatment or repair of neurogenerative diseases and conditions, of epilepsy, and of cerebral 20 ischaemia of various origins.
19. A method of prevention, treatment or repair of neurogenerative diseases and conditions, of epilepsy, and of cerebral ischaemia of various origins in a 25 subject which comprises administering to said subject an effective amount of a compound of formula (I) as claimed in any one of claims 1 to 7 or 13, or a physiologically acceptable acid addition salt thereof. 30
20. Each and every novel compound, process, method, composition and use herein disclosed.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4121821A DE4121821A1 (en) | 1991-07-02 | 1991-07-02 | NEW BENZOMORPHANE AND ITS USE AS A MEDICAMENT |
Publications (2)
Publication Number | Publication Date |
---|---|
IE922144A1 true IE922144A1 (en) | 1993-01-13 |
IE74400B1 IE74400B1 (en) | 1997-07-30 |
Family
ID=6435223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE922144A IE74400B1 (en) | 1991-07-02 | 1992-07-01 | Benzomorphan derivatives |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP0521422B1 (en) |
JP (1) | JP3324785B2 (en) |
KR (1) | KR100251256B1 (en) |
AT (1) | ATE137749T1 (en) |
AU (1) | AU657330B2 (en) |
CA (1) | CA2072814C (en) |
CZ (1) | CZ286949B6 (en) |
DE (2) | DE4121821A1 (en) |
DK (1) | DK0521422T3 (en) |
ES (1) | ES2086585T3 (en) |
FI (1) | FI105913B (en) |
GR (1) | GR3020124T3 (en) |
HK (1) | HK1003111A1 (en) |
HU (1) | HU220873B1 (en) |
IE (1) | IE74400B1 (en) |
IL (1) | IL102361A (en) |
MX (1) | MX9203845A (en) |
NO (1) | NO178263C (en) |
NZ (1) | NZ243388A (en) |
PH (1) | PH31430A (en) |
SG (1) | SG43001A1 (en) |
SK (1) | SK280776B6 (en) |
TW (1) | TW214547B (en) |
ZA (1) | ZA924883B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19528472A1 (en) * | 1995-08-03 | 1997-02-06 | Boehringer Ingelheim Kg | New process for the production of norbenzomorphan of an intermediate stage in the production of pharmaceutically valuable benzomorphan derivatives, in particular of (-) - (1R, 5S, S "R) -3'-hydroxy-2- (2-methoxypropyl -) - 5.9.9 -trimethyl-6.7 benzomorphan |
DE19740110A1 (en) * | 1997-09-12 | 1999-03-18 | Boehringer Ingelheim Pharma | New hydroxy substituted benzomorphan derivatives |
JPH1196519A (en) * | 1997-09-17 | 1999-04-09 | Alps Electric Co Ltd | Spin valve type thin-film element and its production |
US6136980A (en) * | 1998-05-01 | 2000-10-24 | Boehringer Ingelheim Kg | Method of preparing norbenzomorphane as an intermediate in the preparation of pharmaceutically useful benzomorphane derivatives, in particular (-)-(1R,5S,2"R)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzo morphane |
DE19826365A1 (en) * | 1998-06-12 | 1999-12-16 | Gruenenthal Gmbh | Use of benzomorphan derivatives as an analgesic |
DE19957156A1 (en) * | 1999-11-27 | 2001-05-31 | Boehringer Ingelheim Pharma | New amino and fluoro substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine derivatives useful in treatment of e.g. arrythmias, spasms, ischaemia, pain and neurodegenerative disorders |
US6355652B1 (en) | 1999-11-27 | 2002-03-12 | Boehringer Ingelheim Pharma Kg | Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions |
DE10204276A1 (en) * | 2002-02-02 | 2003-08-07 | Boehringer Ingelheim Pharma | N-Allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceuticals |
EP2987788A1 (en) | 2002-05-17 | 2016-02-24 | Taiwanj Pharmaceuticals Co., Ltd. | Opioid and opioid-like compounds and uses thereof |
US7923454B2 (en) | 2002-05-17 | 2011-04-12 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
US7501433B2 (en) | 2002-05-17 | 2009-03-10 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
US8017622B2 (en) | 2003-05-16 | 2011-09-13 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
CL2008003407A1 (en) * | 2007-11-16 | 2010-01-11 | Boehringer Ingelheim Int | Substituted heterobicyclo aryl- and heteroarylcarbonyl derivative compounds; pharmaceutical composition; preparation procedure; and its use in the treatment and / or prevention of metabolic disorders, mediated by the inhibition of the enzyme hsd-1. |
WO2015097545A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7804509A (en) * | 1978-04-26 | 1979-10-30 | Acf Chemiefarma Nv | Novel 6,7-benzomorphan derivatives and their acid addition salts. |
DE2828039A1 (en) * | 1978-06-26 | 1980-01-10 | Boehringer Sohn Ingelheim | 2- (2-ALKOXYETHYL) -2'-HYDROXY-6,7-BENZOMORPHANES THEIR ACID ADDITION SALTS, THESE MEDICINAL PRODUCTS, AND METHOD FOR THE PRODUCTION THEREOF |
NL7907800A (en) * | 1979-10-23 | 1981-04-27 | Acf Chemiefarma Nv | Novel 6,7-benzomorphan derivatives and their acid addition salts, pharmaceutical compositions containing such a compound, and process for the preparation of these compounds and their pharmaceutical compositions. |
-
1991
- 1991-07-02 DE DE4121821A patent/DE4121821A1/en not_active Withdrawn
-
1992
- 1992-06-03 TW TW081104377A patent/TW214547B/zh not_active IP Right Cessation
- 1992-06-27 ES ES92110923T patent/ES2086585T3/en not_active Expired - Lifetime
- 1992-06-27 SG SG1996002082A patent/SG43001A1/en unknown
- 1992-06-27 EP EP92110923A patent/EP0521422B1/en not_active Expired - Lifetime
- 1992-06-27 DE DE59206212T patent/DE59206212D1/en not_active Expired - Lifetime
- 1992-06-27 AT AT92110923T patent/ATE137749T1/en active
- 1992-06-27 DK DK92110923.7T patent/DK0521422T3/en active
- 1992-06-30 IL IL10236192A patent/IL102361A/en not_active IP Right Cessation
- 1992-06-30 NZ NZ243388A patent/NZ243388A/en not_active IP Right Cessation
- 1992-06-30 AU AU18686/92A patent/AU657330B2/en not_active Expired
- 1992-06-30 MX MX9203845A patent/MX9203845A/en unknown
- 1992-06-30 CA CA002072814A patent/CA2072814C/en not_active Expired - Lifetime
- 1992-07-01 KR KR1019920011664A patent/KR100251256B1/en not_active IP Right Cessation
- 1992-07-01 FI FI923050A patent/FI105913B/en not_active IP Right Cessation
- 1992-07-01 HU HU9202199A patent/HU220873B1/en unknown
- 1992-07-01 JP JP17447992A patent/JP3324785B2/en not_active Expired - Lifetime
- 1992-07-01 IE IE922144A patent/IE74400B1/en not_active IP Right Cessation
- 1992-07-01 NO NO922603A patent/NO178263C/en not_active IP Right Cessation
- 1992-07-01 ZA ZA924883A patent/ZA924883B/en unknown
- 1992-07-02 SK SK2075-92A patent/SK280776B6/en not_active IP Right Cessation
- 1992-07-02 CZ CS19922075A patent/CZ286949B6/en not_active IP Right Cessation
- 1992-07-02 PH PH44606A patent/PH31430A/en unknown
-
1996
- 1996-05-31 GR GR960401503T patent/GR3020124T3/en unknown
-
1998
- 1998-03-16 HK HK98102148A patent/HK1003111A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5731318A (en) | Benzomorphan derivatives | |
JP2656702B2 (en) | Peptide quinuclidine | |
IE922144A1 (en) | Benzomorphanes and their use as pharmaceuticals | |
DE60311853T2 (en) | NEW 1,4-DIAZABICYCLOALKAN DERIVATIVES, THEIR PREPARATION AND USE | |
EP0753506A1 (en) | 6-Dimethylaminomethyl-1-phenyl-cyclo-hexane compounds as pharmaceutical agents | |
US4320148A (en) | 2-Aminotetralin compounds, pharmaceutical compositions and method of producing central alpha1 agonist activity | |
US4632935A (en) | Omega-(hydroxy-, ether and ester)-alkyl-2-amino-cycloalkyl- and cycloalkenyl amides as analgesics | |
DE69007905T2 (en) | 1-Oxa-2-oxo-8-azaspiro [4,5] decane derivatives, process for their preparation and pharmaceutical compositions therefrom. | |
US3557127A (en) | Substituted cyclohexenes,derivatives thereof and processes for obtaining same | |
GB1569251A (en) | Pyridobenzodiazepines | |
IE53959B1 (en) | 2,2-disubstituted-ethylamines | |
KR960007864B1 (en) | Sulfonyldecahydro-8h-isoquino(2,1-g)(1,6)naphthyridines, optical isomers thereof and related compounds | |
DE2259282A1 (en) | 2-amino-1-(p-amino phenyl) ethanols - with cardio selective -blocking activity | |
JPH04500690A (en) | pharmaceutical composition | |
US3830818A (en) | Amino quinobenzazepines | |
FI66353B (en) | ANALOGIFICATION OF THERAPEUTIC FREQUENCY OF THERAPEUTIC ANALYSIS 1-AMINO- (LAEGRE-ALKYL) -3,4-DIPHENYL-1H-PYRAZOLER | |
US3583996A (en) | Process for the preparation of certain alkaloid alcohol esters of tropic acid | |
US3676439A (en) | 5,6-dihydro-8,8-dimethyl-3-nitro-8h imidazo(2-1-c) (1,4)oxazine | |
US3274248A (en) | N-1, 1-bis-[aminophenyl]-propyl-amines and salts thereof | |
US4147788A (en) | Antibacterials: 1-difluoromethyl-6,7-methylenedioxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid and its esters | |
US4216324A (en) | 1-Difluoromethyl-6,7-methylenedioxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | |
KR800000541B1 (en) | Process for the preparation of amin-phen-ethanolamines | |
US4281130A (en) | Lower-alkyl 4,6,7,8,8a-9-hexahydro-6,9-ethanothieno[3,2-f]indolizine-10-carboxylate | |
US4284777A (en) | Antibacterials: 1-difluoromethyl-6,7-methylenedioxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid and its esters | |
JPS6183154A (en) | Phenethanolamine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK9A | Patent expired |